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Adiponectin has been shown to improve insulin sensitivity, regulate glucose and lipid metabolism 
and exert anti-atherosclerotic effects. This dissertation, designed as three research papers, aimed to 
examine relationships between diet, weight loss, insulin resistance and adiponectin levels among 
overweight/obese adults who were participating in a behavioral intervention for weight loss. Data 
from the ancillary study to the PREFER trial were used for two of the papers and secondary data 
analysis from the SMART trial was conducted for the third paper. Both parent studies were 
randomized clinical trials that included a behavioral intervention for weight loss. The first study 
compared the effect of a standard calorie- and fat-restricted diet and a calorie- and fat-restricted 
lacto-ovo-vegetarian diet on changes in adiponectin levels at six months (N=143). Weight loss 
was associated with increased total (β(s.e) = -0.71(0.27); P = 0.003) and high molecular weight 
(HMW) adiponectin levels (β(s.e) = -1.37(0.47); P = 0.001); however, they were independent of 
the diet type. The second study examined whether baseline levels or intervention-associated 
changes in adiponectin levels were associated with insulin resistance after six months (N=143). 
At baseline, we found significant inverse associations between total (β(s.e) = -0.26(0.05); P < 
0.001) and HMW(β(s.e) = -0.38(0.09); P < 0.001) adiponectin levels and homeostasis model 
assessment of insulin resistance (HOMA) independent of weight. At six months, there was a 
significant inverse association between changes in total adiponectin and HOMA (β(s.e) = -
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0.17(0.08); P = 0.04) that was independent of baseline weight and weight loss. However, the 
association between changes in HMW adiponectin and HOMA was not significant. The third 
study assessed the longitudinal relationships of weight, waist circumference and body 
composition with adiponectin levels after six and 12 months (N=133). A significant increase in 
adiponectin was observed with significant reductions in weight, body mass index, waist 
circumference, and percent body fat (P for all, < 0.001). Our findings provide evidence for the 
importance of weight loss as a significant public health preventive measure to enhance 
adiponectin levels among the studied population, which could impact the progression of 
atherosclerosis and subsequent cardiovascular disease. 
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1.0    DISSERTATION OBJECTIVES 
Adipose tissue is no longer considered an inert tissue for storing energy but is now recognized as 
an active endocrine organ secreting adipokines, cytokines and a diverse range of inflammatory 
markers1. Adiponectin is one of the adipokines secreted by white adipose tissue and has been 
suggested to improve insulin sensitivity, regulate glucose and lipid metabolism and might play a 
role in the development of diabetes and atherosclerosis2-4. Previous studies suggest that 
adiponectin levels tend to decrease with an increasing body weight and a larger increase in 
adiponectin may occur with a greater weight loss2, 5, 6. 
A lower level of adiponectin in male patients was found to correlate significantly and 
independently with coronary heart disease (CHD)4. Subjects with CHD had lower adiponectin 
levels compared with age and body mass index (BMI) adjusted controls suggesting that 
adiponectin confers a protective effect against atherosclerosis7, 8. Significant negative 
correlations have been described between plasma adiponectin levels and BMI, percent body fat, 
waist-to-hip ratio (WHR) and intra-abdominal fat in adults2. In persons with diabetes, plasma 
adiponectin concentrations were lower in age and BMI-matched non-diabetic men and women3.  
Individuals with lower adiponectin concentrations were found to be at higher risk of developing 
type 2 diabetes than those with higher concentrations suggesting a potential role of adiponectin 
in the pathogenesis of type 2 diabetes9.  In addition, decreased circulating adiponectin levels in 
obesity were associated with higher blood pressure and an increased risk of CHD10, 11. Moreover, 
2 
lower adiponectin levels were linked to future coronary events in men with type 2 diabetes12. 
Furthermore, low plasma adiponectin concentration appeared to be an independent predictor of 
all cause mortality, cardiac mortality and myocardial infarction in patients presenting with chest 
pain13. At a cellular level, adiponectin has been found to suppress inflammation of the vascular 
wall14, suppress the proliferation of vascular smooth muscle cells15 and reduce foam cell 
formation15. The anti-inflammatory properties of adiponectin demonstrated a reciprocal 
association between adiponectin and C-reactive protein in both the blood stream and adipose 
tissue4. 
Results of these studies highlight the importance of exploring potential preventive 
approaches to improve adiponectin levels. There is evidence that a modest intentional weight 
loss through lifestyle changes is an effective means for preventing obesity-associated disorders. 
However, intervention studies focusing on changes in adiponectin level in humans have shown 
mixed results. Thus, the purpose of this dissertation was to better understand the relationship of 
diet, weight loss and insulin with adiponectin. Following are the aims for the dissertation: 
1. Compare the effect of a standard calorie-restricted, low-fat diet (STD-D) vs. a lacto-ovo-
vegetarian diet (LOV-D) on adiponectin levels at six months during a 12-month lifestyle 
intervention intended to achieve weight reduction. 
2. Determine whether baseline or intervention-associated changes in adiponectin levels 
were associated with insulin resistance after six months of behavioral treatment for 
weight loss. 
3. Assess the longitudinal relationships between weight, waist circumference, body 
composition and adiponectin levels at six and 12 months of a behavioral intervention for 
weight loss. 
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2.0 BACKGROUND 
2.1 ADIPOSE TISSUE 
Adipose tissue is no longer considered an inert tissue mainly devoted to energy storage but is 
now recognized as an active endocrine organ secreting several hormones and a diverse range of 
other protein factors16. In general, adipose tissue can be divided into two major types: white 
adipose tissue (WAT) and brown adipose tissue. WAT is composed of mainly adipocytes and 
other distinct cell types including mature adipocytes, pre-adipocytes, fibroblasts and 
macrophages, all of which participate, to a greater or lesser extent in WAT secretary functions1. 
A number of proteins secreted by adipocytes are called adipocytokines. Leptin, adiponectin, 
vistafin, and resistin are a few of the well known adipocytokines.   Macrophages in WAT also 
secrete a number of cytokines including interleukin-6 (IL-6), tumour necrosis factor alpha 
(TNFά), interleukine-5 (IL-5), macrophage chemoattractant protein (MCP). All hormones and 
protein molecules secreted by adipose tissue are collectively called adipokines. The number and 
range of adiposity secretary proteins is continuing to expand rapidly and approximately 50 
different molecular entities have been identified so far16.  
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2.1.1 Adiponectin 
  
Adiponectin, also known as adipoQ, Acrp30, apM1 and GBP28, is a protein molecule that is 
secreted by the adipocytes of WAT.  There is a tendency for reduced adiponectin levels in obese 
individuals and increased levels in those with anorexia nervosa17, 18. Other studies described a 
significant negative correlation between BMI and plasma adiponectin levels in both men and 
women and that adiponectin levels are negatively correlated with percent body fat, waist–to-hip 
ratio and intra-abdominal fat2, 6. The secretion of adiponectin into the bloodstream is not 
regulated by subcutaneous but rather by visceral adipose tissue19. 
  Furthermore, plasma adiponectin concentrations are reported to increase following 
weight loss3, 20. In patients with diabetes, plasma concentrations are lower in age and BMI-
matched non-diabetic men and women3.  Adiponectin concentrations correlate negatively with 
fasting plasma insulin concentrations and 2-hr glucose concentrations in glucose tolerance test 
and correlate positively with insulin sensitivity2, 6.  In examining lipid profiles, serum 
triglycerides levels correlated negatively and high density lipoprotein cholesterol levels 
correlated positively with plasma adiponectin levels3. In a study with Pima Indians, individuals 
with high adiponectin concentrations were found to be at lower risk of developing type 2 
diabetes than those with low concentrations suggesting a potential role of adiponectin in the 
pathogenesis of type 2 diabetes9. 
The normal plasma level for adiponectin in healthy humans is 1.9-17.0 mg/dl with 
significantly lower levels reported in obese subjects17. Hypoadiponectinemia, a plasma 
adiponectin level of  < 4.0 ug/ml, in males was found to correlate significantly and independently 
with coronary artery disease (CAD)4. Individuals with CAD have lower adiponectin levels 
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compared with age and BMI adjusted controls8 suggesting that adiponectin, in contrast to other 
adipokines, confers a protective effect against atherosclerosis. Also, decreased circulating 
adiponectin levels in obesity are associated with an increased risk of CAD10, 11. Additionally, 
adiponectin is linked to future coronary events in men with type 2 diabetes12. Low plasma 
concentration is an independent predictor of all cause mortality, cardiac mortality and 
myocardial infarction in patients presenting with chest pain13.  
 Adiponectin reduces the production of TNF-ά21 and inhibits IL-6 production22.  
Adiponectin and TNF-ά mutually inhibit each other’s production in adipose tissue and 
adiponectin can counteract the pro-inflammatory effects of TNF-ά  in vascular cells23. Since IL-6 
induces the release of hepatic VRP, adiponectin may indirectly inhibit IL-6 and CRP expression. 
It also suppresses the transformation of macrophages to foam cells17. 
It has been reported that circulating adiponectin is present in three distinct forms; low 
molecular weight (LMW), medium molecular weight (MMW) and high molecular weight 
(HMW) form24. Although the precise biological activities of these forms are not well understood, 
it has been suggested that HMW adiponectin is the most active form of adiponectin25. HMW 
adiponectin has been reported to be an important factor in explaining the metabolic syndrome26, 
27 and is more closely associated with the insulin resistance syndrome than total plasma 
adiponectin level25, 26. Also, HMW adiponectin has been reported to confer a protective effect 
against coronary artery disease28. However, many intervention studies that included a low-calorie 
diet that induced weight loss have been limited by the measurement of only total adiponectin. 
Hence, little is known about the changes in the HMW level relative to the total adiponectin level 
induced by such interventions.  
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In summary, adiponectin levels are decreased in obesity and are inversely correlated with 
insulin resistant states in obesity. Adiponectin has been shown to inhibit the TNF-ά induced 
changes in monocyte adhesion molecule expression and in the endothelial inflammatory 
response8. Adiponectin concentrations were negatively correlated with WHR, independent of 
gender and overall adiposity19. Taken together, adiponectin appears to act as an anti-
inflammatory molecule with some protection against diabetes and atherosclerosis 29. 
 
2.1.2 Obesity and Inflammation 
Obesity, particularly visceral adiposity, is associated with chronic low-grade inflammation, as 
indicated by an increased level of inflammatory markers in the circulation of obese subjects. The 
WAT of obese individuals contains an increased number of macrophages compared with that of 
lean persons with a possibility of higher secretion of pro-inflammatory molecules. It has been 
hypothesized that adipokines, cytokines and other factors produced and secreted by WAT are 
responsible for the chronic inflammatory state of visceral obesity. The combination of 
inflammation, hypertension and dyslipidemia increases the likelihood of development of type 2 
diabetes and CVD30. However, the ultimate reason for increased production of pro-inflammatory  
factors by WAT in obesity has not been identified31. 
One of the key developments in obesity research over the past four years is the 
recognition that the disorder is characterized by chronic mild inflammation30. The main basis for 
this view is that there is an increased circulating level of inflammatory markers in the obese 
individuals. Given the observation that WAT expresses and secretes a number of inflammation-
related proteins, it is probably that it is a major source of the increase in inflammatory markers in 
obesity thereby increasing risks for the development of diabetes and CVD.  
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On the basis of available evidence, it could be hypothesized that the increased release of 
pro-inflammatory adipokines, mainly IL-6 and TNF-ά from the visceral adipose tissue along 
with reduced secretion of anti-inflammatory adipokines and cytokines, mainly adiponectin and 
IL-10 can generate a low grade chronic inflammatory state. This imbalance of pro-inflammatory 
and anti-inflammatory adipokines might play a role in the future development of diabetes and 
atherosclerosis through both a reduced insulin sensitivity and endothelial dysfunction. Figure 1 
depicts a proposed mechanism linking adiposity and adiponectin with chronic diseases, such as 
atherosclerosis and diabetes.  
   Obesity 
(Visceral fat) 
 
 
IL-6       Adiponectin 
TNF ά, Leptin      IL-10 
 
   
                                                    Pro-inflammatory state 
 
 
Insulin resistance   Endothelial dysfunction 
        
 
                                                     Diabetes 
                                                  Atherosclerosis 
 
Figure 2-1 Proposed link among adiposity, adiponectin and diabetes or atherosclerosis  
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2.2     ADIPONECTIN AND DIET 
Epidemiological studies have suggested that increased adiponectin levels are associated with 
consuming deep yellow vegetables32, a Mediterranean-type diet33, moderate alcohol34, having a high 
score for the dietary pattern characterized by a high intake of fresh fruits35 and adherence to a healthy 
dietary pattern as measured by an alternate healthy eating index36. A dietary pattern characterized by 
high consumption of whole-grain cereals and low-fat dairy products and low consumption of refined 
cereals was positively associated with adiponectin levels in healthy women37. Observational studies 
have revealed significant negative associations between higher energy intake, lower physical activity 
and adiponectin levels among women38 and men32.  
However, short-term controlled studies examining the effect of a very-low calorie diet 
(VLCD) on adiponectin levels in small groups of adults have shown conflicting results. Anderlova et 
al.39 did not find significant changes in adiponectin levels in obese women after a VLCD (550 
cal/day) for three weeks. Additionally, obese women consuming a liquid diet of 800 cal/day for four 
weeks did not significantly increase adiponectin levels40. Xydakis et al.41 examined the impact of a 
VLCD (600-800 cal/day) on adiponectin in obese adults with and without the metabolic syndrome 
(MS) for 6-8 week duration and found no change in adiponectin levels in both groups. However, in a 
similar study between subjects with and without the MS, adiponectin levels in both groups increased 
after administration of a VLCD (450 cal/day) for 16 weeks followed by two weeks of re-feeding42. 
The possible explanation for the inconsistent findings of these studies might be variations in type and 
duration of the VLCD and also the populations studied. The generalizability of these findings may be 
limited due to the severe restrictiveness of the VLCD. In order to consider the beneficial effects of 
diet on adiponectin for an intervention, it is essential to examine the relationship between adiponectin 
and a diet that individuals can follow for the long term.  
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Although a hypocaloric diet induced weight loss and usually improved co-morbidities 
associated with obesity in several descriptive studies, the circulating adiponectin levels remained 
either unchanged43, increased44-46 or even decreased47. Dvarakova-Lorenxova et al.43 reported no 
change in adiponectin levels after nine weeks of dietary education and supervised physical activity in 
90 obese women, but limited detail was provided regarding the type of diet. In contrast, a 12-week, 
low caloric, low-fat diet among 20 overweight/obese premenopausal women resulted in a 36% 
increase of adiponectin levels46. Similarly, Brunn et al.45 reported increased adiponectin levels 
following a 15-week lifestyle intervention among 23 severely obese subjects. Increased adiponectin 
levels were observed among 21 obese children while receiving a psycho-educational intervention 
suggesting that adiponectin in obese children can be normalized44.Similar improvements in 
adiponectin levels were reported in104 overweight and obese children after a 12-month lifestyle 
intervention48. Conversely, decreased adiponectin levels were found among 15 healthy, normal-
weight women after following a 4-week low caloric diet47. In summary, these studies reported 
inconsistent findings and had several limitations, in particular a small sample and a brief intervention 
period. Thus, the evidence provided by these studies is inconclusive about the effect of diet on 
adiponectin levels.  
Results of randomized clinical trials have also been inconsistent regarding the effects of 
dietary factors on adiponectin levels. No changes were observed in adiponectin following either a 
moderate fat/moderate carbohydrate or low fat/high carbohydrate diet in obese women for 10 
weeks49. Similarly, Cardillo et al.50, deLeu et al.51 and Keogh et al.52 found no difference in 
adiponectin levels between the two groups of obese individuals that were randomly assigned to either 
a low carbohydrate or a low fat diet for a period of 12 months, 36 months or 12 weeks, respectively. 
Additionally, no significant changes were found in adiponectin levels in the lifestyle intervention 
group when compared with insulin treatment and combined treatment of insulin and lifestyle 
intervention in adults with type 2 diabetes for one year53. A marginal increase in adiponectin levels 
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was observed in the diet and exercise intervention group when compared with the control groups in 
obese women after 14 weeks54 and non obese healthy women after 12 months55.  
No differences in adiponectin were observed between the lifestyle intervention and the 
control groups in obese adolescents over a one-year period56. Compared with the control group, a 
significant increase in adiponectin was observed in the group following a lifestyle intervention that 
included a Mediterranean-style diet57. A moderately low-fat diet intervention produced favorable 
changes in adiponectin levels in comparison with the weight maintenance intervention over a 16-
week intervention58. Similarly, a one-year hypocaloric dietary intervention had a significant positive 
effect on adiponectin levels compared with the exercise, the diet and exercise and the control 
groups59. A significant improvement in adiponectin levels was observed at three months in the fiber 
supplementation group when compared with the placebo group, suggesting a possible role of specific 
dietary factors on adiponectin60. 
There is ample evidence that following a vegetarian diet may be beneficial to general and 
cardiovascular health. This eating pattern has been linked to less weight gain61, improved lipid 
profile62 and increased body leanness63 compared to those following a carnivorous diet. There is 
substantial evidence that the amount and type of foods eaten have profound effects on risk 
factors for CHD (lipid, glucose, insulin). Thus, it is plausible that adiponectin also can be 
significantly affected by changes in dietary composition. An understanding of adiponectin 
physiology in response to various diets could be of value in identifying a more beneficial diet to 
prevent or reduce the inflammatory state that is associated with the development of diabetes and 
CHD. 
 In summary, the effect of diet on serum adiponectin level varies depending on the type of 
diet consumed, the study population, and duration of the dietary intervention. Although inconclusive, 
many studies suggest that adiponectin levels might be modified by dietary intake. What remains 
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unknown is the effect of a LOV-D on adiponectin levels in healthy overweight/obese adults who are 
participating in a behavioral and dietary intervention for weight loss over a longer period.   
2.3     ADIPONECTIN AND BODY WEIGHT 
Several studies have reported decreased adiponectin levels in obese individuals compared with 
normal weight individuals17, 20, 64. Significant negative correlations have been described between 
adiponectin levels and BMI, percent body fat, WHR and intra-abdominal fat in adults2, 6, 65. The 
Cardia Study showed decreased adiponectin levels with increasing weight and intra-abdominal fat 
during five years of observation66. Weight loss has been found to increase adiponectin concentration3, 
20, 67 and there is a tendency for increased levels to be present in those with anorexia nervosa17, 18 
suggesting body fat content to be a major determinant of circulating adiponectin. Lifestyle induced 
weight loss has been found to increase adiponectin levels among obese women57, non obese adults68, 
insulin resistant obese adults69 and children44.  
Not all studies have shown an increase in adiponectin with weight loss in obese women40, 43, 
49, 70 obese adults51, lean and obese women39, 71 and obese adults with and without MS41. One study72 
suggested a need for relatively large weight loss for improvement in adiponectin in obese adults. 
Because of the variations due to study population, sample size, differences in baseline weight and the 
amount of weight lost, the evidence provided by these studies is inconclusive about the effect of 
weight loss on adiponectin levels.   
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2.4    ADIPONECTIN AND INSULIN RESISTANCE 
 
Adiponectin levels have been shown to be lower in insulin-resistant individuals73. In a study of Pima 
Indians, those with high adiponectin concentrations were found to be at lower risk of developing type 
2 diabetes than those with low concentrations suggesting a potential role of adiponectin in the 
pathogenesis of type 2 diabetes9. A similar inverse relationship between adiponectin levels and 
incidence of insulin resistance has been shown in follow-up studies among young adults66, adults74, 
adults with impaired glucose-tolerance75 and elderly men76. Interestingly, adiponectin levels were 
found to be low among individuals with insulin-resistance regardless of their BMI73 and were 
inversely associated with insulin resistance independent of obesity among adults77. This degree of 
association between adiponectin and insulin resistance seemed stronger in overweight than in 
normal-weight adolescents78 and in adults with the MS than without the MS79. Moreover, adiponectin 
was independently related to all components of the MS in young adults80. Similarly, an inverse 
association between adiponectin levels and the risk for diabetes was reported among a large 
population of healthy women81 and a middle-aged population cohort82.  
The findings of these studies suggest that an increase in adiponectin levels may contribute to 
improved insulin sensitivity and may provide a molecular link between adiposity and diabetes. 
However, adiponectin levels did not increase despite improved insulin sensitivity in response to 
moderate weight loss among obese women73, 83, adults41, 84 and increase in physical activity among 
overweight individuals85 and healthy men86. Improvement in insulin sensitivity was not related to 
adiponectin levels in the intervention and the control groups among adults with impaired glucose 
tolerance87. These inconsistent findings may partly be explained by differences in either the baseline 
degree of insulin resistance, adiponectin levels and/or the improvement in insulin resistance and 
adiponectin levels after each intervention. Recent findings have suggested that the improved insulin 
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sensitivity induced by changes in adiponectin levels may not result from a short term intervention88. 
Hence, there is a substantial need to examine prospectively the association between adiponectin and 
insulin sensitivity in a population at increased risk of developing diabetes before enrolling in the 
study.   
 
 
14 
3.0    WEIGHT LOSS IS MORE IMPORTANT THAN THE TYPE OF DIET IN 
IMPROVING ADIPONECTIN LEVELS AMONG OVERWEIGHT/OBESE ADULTS 
Sushama D. Acharya, MS1,2 ; Maria M. Brooks, PhD2; Rhobert W. Evans, PhD2; 
Faina Linkov, PhD2,3; Lora E. Burke, PhD, MPH1,2 
                                   
 
1University of Pittsburgh School of Nursing, Pittsburgh, PA, USA 
2University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA 
3University of Pittsburgh School of Medicine, Pittsburgh, PA, USA 
 
 
 
(Manuscript in Preparation) 
 
 
 
 
 
 
 
15 
3.1    ABSTRACT 
Background: Studies have suggested that adiponectin levels may be modified by dietary intake 
and weight loss.   
Objective: To compare the effect of a standard calorie- and fat-restricted diet (STD-D) and a 
calorie- and fat-restricted lacto-ovo-vegetarian diet (LOV-D) on changes in total and high 
molecular weight (HMW) adiponectin levels at six months of a behavioral weight loss 
intervention trial. 
Methods: We delivered the 12-month behavioral intervention to both groups; the only difference 
was that the LOV-D participants were instructed to eliminate meat, poultry, and fish from their 
diet. Weight, total and HMW adiponectin levels and dietary intake using a 3-Day Food Record 
were measured. 
 Results: The sample included 143 adults (STD-D=79; LOV-D=64) and was 88% female, 67% 
White (mean BMI = 33.7 kg/m2). We found no differences in weight, total and HMW 
adiponectin levels between the two groups at baseline. At six months, both groups had 
significantly increased total (STD-D [+ 7.2 ± 17.8] %; LOV-D [+ 9.4 ± 21.8] %) and HMW 
adiponectin levels (STD-D [+ 18.5 ± 32.9] %; LOV-D [+ 15.8 ± 34.5] %) (P = < 0.05) with no 
significant differences between the groups. We found significant associations between weight 
loss and changes in total (β(s.e) = -0.71(0.27); P = 0.003) and HMW adiponectin (β(s.e) = -
1.37(0.47); P = 0.001) levels independent of the diet type. Weight loss at the higher quartile was 
associated with improvements of total and HMW adiponectin levels (P < 0.05). 
Conclusion: Weight loss was associated with improved total and HMW adiponectin levels 
regardless of the diet type.  
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3.2     INTRODUCTION 
Adiponectin is an adipocytokine with anti-inflammatory properties that may play a role in the 
development of insulin resistance6, diabetes3 and atherosclerosis11. At the cellular level, 
adiponectin has been found to suppress inflammation of the vascular wall14 and proliferation of 
vascular smooth muscle cells15 and also reduce foam cell formation29. Additionally, 
epidemiological studies have suggested that adiponectin also plays an important role in the 
development and progression of several obesity-related cancers, such as endometrial cancer89, 
postmenopausal breast cancer90 and colon cancer91. Adiponectin levels tend to decrease with an 
increasing body weight and increase with weight loss3. There is substantial evidence that the 
amount and type of foods eaten have profound effects on risk factors for diabetes and 
atherosclerosis. Hence, it is plausible that adiponectin can also be significantly affected by 
changes in dietary composition. Thus, it is important to explore if a preventive approach that 
includes diet is a feasible intervention strategy to improve adiponectin levels.   
It has been reported that circulating adiponectin is present in three distinct forms; low 
molecular weight (LMW), medium molecular weight (MMW) and high molecular weight 
(HMW) form24. Although the precise biological activities of these forms are not well understood, 
it has been suggested that HMW adiponectin is the most active form of adiponectin25. HMW 
adiponectin has been reported to be an important factor in explaining the metabolic syndrome26, 
27 and is more closely associated with the insulin resistance syndrome than total plasma 
adiponectin level25, 26. Also, HMW adiponectin has been reported to confer a protective effect 
against coronary artery disease28. However, many intervention studies that included a low-calorie 
diet that induced weight loss have been limited by the measurement of only total adiponectin. 
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Hence, little is known about the changes in the HMW level relative to the total adiponectin level 
induced by such interventions.  
 Epidemiological studies have suggested that increased adiponectin levels are associated 
with consuming deep yellow vegetables32, a Mediterranean-type diet33, having a high score for 
the dietary pattern characterized by a high intake of fresh fruits35 and adherence to a healthy 
dietary pattern as measured by an alternate healthy eating index36. A dietary pattern characterized 
by high consumption of whole-grain cereals and low-fat dairy products and low consumption of 
refined cereals was positively associated with adiponectin levels37. However, dietary 
interventions examining the effects of the type of diet on adiponectin have shown conflicting 
results. Although diet induced weight loss usually improved co-morbidities associated with 
obesity, the adiponectin levels remained either unchanged41, 49-52, 56, increased20, 57, 64, 92 or 
decreased47. Similarly, a few studies of changes in HMW adiponectin levels following an 
intervention have shown either no changes in distribution of adiponectin forms93, increase in 
HMW24, 28 or increase in all three forms46. However, these studies had several limitations, 
specifically a limited sample size24, 28, 46, 93 and a brief intervention period28, 46. Thus, the 
evidence provided by these studies is inconclusive about the effects of diet on HMW adiponectin 
levels.  
There is ample evidence that following a vegetarian diet may be beneficial to general and 
cardiovascular health. This eating pattern has been linked to less weight gain61, improved lipid 
profile62 and increased body leanness63 compared to those following a carnivorous diet. The 
literature also suggests that adoption of a vegetarian eating plan may be sustained longer than 
other weight-reducing eating plans94. Recently, Barnard et al.95 reported similar acceptability 
between a low-fat vegan diet and a more conventional diabetes-management diet.  However, no 
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identified studies examined the effect of a lacto-ovo-vegetarian diet on adiponectin levels. 
Therefore, the purpose of this study was to compare the effect of a standard calorie- and fat-
restricted diet (STD-D) vs. a lacto-ovo-vegetarian diet (LOV-D) on total and HMW adiponectin 
levels at 6 months during a 12-month lifestyle intervention intended to achieve weight reduction.  
3.3    METHODS 
3.3.1 Study Design 
This was an ancillary study to the PREFER (Paving the road to everlasting food and exercise 
routine) trial. The design, recruitment and randomization procedures for the PREFER trial have 
been described in detail elsewhere 96. PREFER is an 18-month behavioral weight loss study that 
examined the effects of 2 dietary options; STD-D vs. LOV-D by whether or not subjects received 
their preferred dietary treatment (Preference-Yes vs. Preference-No). Participants were randomly 
assigned first to one of the two preference conditions (yes or no). If assigned to Preference-No 
condition, they were further randomly assigned to one of the two diet conditions (STD-D or 
LOV-D). If assigned to Preference-Yes condition, they were assigned to the diet they indicated 
as preferred at screening.  
The present ancillary study merged the data of the two preference groups and compared 
the changes from baseline to six months between the two diet groups: STD-D and LOV-D. The 
study protocol was approved by the University of Pittsburgh Institutional Review Board; all 
participants provided written informed consent and all procedures were followed in accordance 
with the ethical standard of this board. The PREFER trial was conducted between 2000 and 
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2005.  The current analysis was limited to the 143 participants whose sera samples were 
available from both baseline and 6-month assessments.  
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3.3.2 Study Population 
Eligibility criteria required that individuals were between 18 and 55 years of age; had a body 
mass index (BMI) between 27 and 43 kg/m2 inclusively and had completed a 5-day Food Record 
at screening. Individuals were excluded if they had a current medical condition requiring 
physician supervision of diet or physical activity; were pregnant or had intention to become 
pregnant during the study period; reported alcohol intake of ≥ 4 drinks/day; were participating in 
any weight-loss program in the last 6 months, taking any medication to induce weight loss; or 
reported abstention from eating meat, poultry, or fish in the past month.  
3.3.3 Intervention 
The same behavioral intervention was delivered to all treatment groups in the weekly group 
sessions during the first six months. The only difference was that the LOV-D participants were 
instructed to eliminate meat, poultry, and fish from their diet by the sixth week of the program. 
They were permitted to eat dairy products, eggs and meat flavorings. The cognitive-behavioral 
intervention used several strategies from conceptual models of motivation and behavior change. 
All participants received nutritional and behavioral counseling to develop skills to implement a 
healthy lifestyle. Several approaches were used to promote session attendance and adherence to 
the treatment protocol. Incentives to promote attendance included receiving either Cooking Light 
for the STD-D diet group or Vegetarian Times for the LOV-D diet group at the session.  
In both groups, the goal of the intervention was to restrict calories and replace total fat 
intake, especially saturated fatty acids, with increased intake of fruit, vegetables and whole grain 
products. In addition, participants in the LOV-D were counseled on how to follow a LOV-D and 
21 
suggested to incorporate several plant based foods, such as lentils, beans and soy products to 
replace meat products. Numerous vegetarian foods were sampled in the LOV-D group sessions 
while the STD-D group sampled low fat foods.  
Participants received daily dietary goals based on gender and baseline body weight. For 
participants weighing < 200 lbs, the prescribed calorie intake was 1200 kcal for women and 1500 
kcal for men. For those weighing ≥ 200 lbs, the goal was 1500 kcal for women and 1800 kcal for 
men. The fat gram goal was 25% of the total calories for everyone. Participants were instructed 
to increase their physical activity to reach a weekly goal of 150 minutes by week six. We 
instructed participants to record daily in a paper diary their energy, fat intake and the minutes of 
physical activity performed. Completed diaries were collected at each session. The 
interventionists reviewed the diaries and returned them to the participants with written feedback 
at the next session. The feedback was comprised of suggestions based on personal preference 
and culture on how the diet could be improved in the respective groups.  
3.3.4 Measures 
Sociodemographics. Baseline sociodemographic characteristics were collected via a self-
administered, standardized questionnaire. Information obtained included age, gender, race, 
marital status, education and income.  
Dietary assessments. At baseline and 6 months, participants were instructed to complete a 3-
Day Food Record and asked to record dietary intake on twp work days and one leisure day. 
Project staff reviewed the diary with the participant to ensure that full detail on foods consumed 
was provided. The data were analyzed using the Nutrition Data System for Research software 
(Nutrition Coordination Center, University of Minnesota, Minneapolis, MN) by staff at the 
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Obesity/Nutrition Research Center who were blinded to the treatment group and assessment 
period.  
Adherence to the LOV-D.  Adherence to the LOV-D was based on whether participants 
reported any meals containing meat, poultry or fish on the 3-Day Food Record at six months 
(100% adherence: reported no meat, poultry or fish; < 100% adherence: reported ≥ one  meal 
containing meat, poultry or fish).  
Physical Activity Assessments.  The total energy expenditure for the past seven days was 
collected via a self-administered Paffenbarger Activity Questionnaire. This questionnaire has 
been shown to have good test-retest reliability 97. A metabolic equivalent value was assigned to 
each leisure activity, from which the total energy expenditure was calculated.  
Anthropometric and biochemical measurements.  We measured weight on a digital scale 
(Tanita Corporation of America, Inc., IL) with the person in light clothing and without shoes. 
Height was measured on a wall-mounted standiometer.  BMI was computed using the following 
formula:  BMI = weight (kg) /height (meters2). Blood samples, obtained following a 12-hour 
overnight fast were assayed at the Heinz Nutrition Laboratory, University of Pittsburgh. 
Analyses of serum triglyceride and high density lipoprotein (HDL) levels were conducted 
enzymatically using the ATAC 8000 autoanalyzer (Vital Diagnostics, Lincoln, RI).  LDL was 
estimated using the Friedewald equation. All measures were obtained at baseline and six months. 
Adiponectin measurements.  The values of total adiponectin and HMW adiponectin were 
obtained from the stored samples of the PREFER study. Sera from each assessment point were 
stored at -80oC at the School of Nursing Laboratory. Serum levels of total and HMW adiponectin 
were determined using an ELISA technique (ALPCO Diagnostics, Salem, NH).  The samples (10 
µL) were pretreated with separate proteases for determination of total and HMW adiponectin, 
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respectively. After pretreatment, all samples were incubated for 60 minutes at room temperature 
(RT) in wells coated with anti-human adiponectin monoclonal antibodies. The plates were 
washed and a second adiponectin monoclonal antibody, with an independent epitope, and labeled 
with biotin was added. The plates were again incubated for 60 minutes at RT, washed and 
horseradish labeled streptavidin added. The plates were incubated for 30 minutes at RT, washed 
and substrate solution (O-phenyldiamine) added and the plates incubated for 10 minutes at RT. 
The reaction was stopped with H2SO4 and the absorbance read at 492 nm.  Blanks, standards 
(0.075 to 4.8 ng/mL) and control pools were run with each set of samples. The intra-assay and 
inter-assay co-efficient of variations (CV) were 6.4% and 12.7% for total adiponectin and 6.4% 
and 12.6% for HMW adiponectin, respectively.  All samples were assayed in duplicate. The 
analyses were performed at the Heinz Nutrition Laboratory, Graduate School of Public Health at 
the University of Pittsburgh.  
 
3.3.5    Statistical Analysis 
 
All continuous variables were checked for normality. Data are expressed as mean ± SD   or as 
proportions. Comparisons between the two groups were examined using an independent samples 
t-test, a Mann-Whitney test or a chi-square test. A paired t-test or Wilcoxon's matched pairs test 
was used for assessing changes within the groups. Associations between variables were assessed 
with the Pearson or Spearman correlation coefficient. A multiple linear regression was used on 
percent change in total and HMW adiponectin separately as the dependent variables with the diet 
types adjusting for age, gender, race, baseline weight, baseline energy expenditure, changes in 
weight and energy expenditure. Two possible interactions were explored (the diet groups and 
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weight loss; weight loss and gender) and included in the model only if found to be statistically 
significant. A one-way analysis of variance was used to compare changes in adiponectin levels 
by quartiles of weight change. The significance level was set at < .05. Statistical analyses were 
performed using SAS (version 9.2; SAS Institute Inc, Cary, NC).  
3.4    RESULTS 
Sera samples of 143 (95%) of the 151 participants who completed the 6-month assessment were 
available. No differences in baseline characteristics were found among participants who were 
excluded when compared with participants included in the analysis.  The study sample included 
143 adults (STD-D = 79; LOV-D = 64) with a mean BMI of 33.7 kg/m2 and was 88% female, 
67% White, and 44.2 ± 8.5 years old. We found no differences in age, education, weight, BMI, 
dietary intake, total and HMW adiponectin levels between the two groups at baseline (Table 1). 
Compared to males, females had significantly higher total (7.85 ± 3.32 vs. 6.31 ± 2.58 ug/ml; P 
= .04) and HMW adiponectin levels (3.37 ± 2.9 vs. 2.39 ± 1.43 ug/ml; P = 0 .03).  
At six months, the STD-D group significantly increased total adiponectin by 7.2 % (P = 
.04) and HMW adiponectin levels by 18.5% (P = .001) compared with baseline levels. The 
LOV-D group also significantly increased total adiponectin by 9.4% (P = .01) and HMW 
adiponectin levels by 15.7% (P = .02). However, differences in the 0 – 6 month levels of total 
adiponectin (P = .51) and HMW adiponectin (P = .62) between the two groups were not 
significant (Table 2). Analysis was also conducted excluding participants who reported <100% 
adherence to the LOV-D (n = 23). There were no statistically significant differences in the  
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changes of total and HMW adiponectin levels between the STD-D and the 100% adherent LOV-
D groups.  
There was a significant decrease in body weight within both groups (p for all < .001); 
with no significant difference in weight loss between the two groups (P = .5). Overall, males lost 
significantly more weight than females (-13.5 ± 6.5 vs. – 8.1 ± 5.8 %; P < .001) with 
significantly greater improvement in total (19.8 ± 18.5 vs. 6.7 ± 19.4%; P = .01) and HMW 
adiponectin levels (41.1 ± 36.9 vs. 14.3 ± 32.0%; P = .002). We observed a highly significant 
correlation between total and HMW adiponectin levels at baseline (r = .95; P < .0001) and 6 
months (r = .95; P < .0001). Total energy intake and fat intake decreased in both groups (P = 
<.0001) with no differences between the groups.  Similarly, both groups increased carbohydrate 
intake (P = <.0001), but this increase was significantly higher in the LOV-D group (P = .01) than 
in the STD-D group.  The STD-D groups increased protein intake (P = .001) but no change in 
total protein intake was observed in the LOV-D group. The LOV-D group reduced animal 
protein intake (P = .004) but the STD-D group increased this intake of this food group (P = .001) 
(Table 2).  
In multiple linear regression analysis, weight loss was significantly and independently 
associated with changes in total (P = .003) and HMW adiponectin levels (P = .001). However, 
the diet type was not associated with total (P = .64) or HMW adiponectin levels (P = .48) (Table 
3). In order to further examine the effects of weight change on adiponectin, we divided the 
sample into quartiles of weight change and found a significant increase in total (P = .008) and 
HMW adiponectin levels (P = .008) with weight change by quartile. Post hoc analyses revealed 
a significant improvement in total adiponectin level between weight change at the first and the 
fourth quartile (P  < .05) and also between the first and the third quartiles (P  < .05). Similarly, a 
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significant increase in HMW adiponectin level was observed with weight change between the 
first and the fourth quartile (P < .01) (Figure 1).  
3.5    DISCUSSION 
We found significant increases in total and HMW adiponectin levels in response to both diets, 
however, the LOV-D did not modify adiponectin levels to a different degree than the STD –D at 
six months. Weight loss was associated with increased total and HMW adiponectin levels, 
independent of the diet type. Moreover, we also demonstrated a need for a greater weight loss to 
significantly improve adiponectin levels in this population.  
To our knowledge, this is the first study to compare the effect of STD-D and LOV-D on 
adiponectin levels. A significant decrease in weight and improvements in adiponectin levels in 
both groups suggest that both diets are equally effective in weight reduction and improvement of 
adiponectin levels. Moreover, comparable changes were observed in serum lipids levels in both 
groups, which may indicate that the type of diet might not be as important and that more than 
one dietary approach may be followed based on individual preferences and metabolic needs, 
provided that the weight loss is maintained. However, we cannot rule out the possibility of 
specific food groups having positive effects on adiponectin levels. In particular, studies have 
suggested that increased adiponectin levels are observed with consumption of a high intake of 
dietary fiber33, 37, 98, 99, deep yellow and green vegetables32 and moderate alcohol intake34. 
Longitudinal studies are required to determine further relationships between the food groups and 
adiponectin levels. 
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Several studies have examined the relationship between dietary interventions and 
adiponectin levels. No changes were observed in adiponectin level following either a moderate 
fat/moderate carbohydrate or low fat/high carbohydrate diet in obese women49. Similarly, there 
were no differences in adiponectin levels between the two groups of obese individuals randomly 
assigned to either a low carbohydrate or a low fat diet50-52, 100.  Xydakis et al.41 examined the 
impact of a VLCD on adiponectin in obese adults with and without the metabolic syndrome and 
found no change in adiponectin levels in both groups. No differences in adiponectin levels were 
observed between a low fat diet and the control groups in obese adolescents56. In contrast, 
compared with the control group, a significant increase in adiponectin level was observed 
following a lifestyle intervention that included a Mediterranean-style diet57. A significant 
increase in adiponectin level was observed after weight loss was induced by gastric bypass 
surgery20, 92 and with a calorie-restricted diet among individuals with type 2 diabetes3. A high 
monounsaturated fat diet was associated with greater improvements in adiponectin levels when 
compared to a high carbohydrate-or protein diet among weight stable hypertensive adults101. 
The possible explanations for these inconsistent findings might be due to variations in 
type and duration of intervention, sample size, individual variations in adiponectin levels and the 
populations studied. However, a major consistency found in all studies that failed to show 
improvements in adiponectin levels was a significant but small weight loss. On the contrary, 
studies with significant improvements in adiponectin levels had at least a 10% weight loss. These 
observations have led some investigators to suggest that a threshold of at least a 10% weight loss 
is essential to observe significant improvements in adiponectin levels40, 72, 93.  
We found a linear relationship with mean weight loss of 8.72% and improvements in 
total and HMW adiponectin levels; however, a modest clinically meaningful weight loss of 5% 
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was not enough to observe significant improvements in adiponectin levels. We observed a 
significant improvement in total adiponectin at the third and fourth quartiles of weight loss while 
a similar improvement in HMW adiponectin occurred only at the fourth quartile suggesting that 
weight loss of at least 8% and 12% might be necessary to observe significant improvements in 
total and HMW adiponectin levels, respectively. Our findings are consistent with the findings of 
others who have reported a need for substantial weight reduction to increase adiponectin levels40, 
72, 93, 102, 103. The requirement of a greater weight loss for a marked increase in total and HMW 
adiponectin levels is further strengthened by our findings that significantly greater improvements 
in adiponectin levels were paralleled with a significantly greater weight loss among men when 
compared to women, despite women having significantly higher levels adiponectin levels at 
baseline. As suggested by Weyer et al.6, these results indicate a negative feedback mechanism of 
obesity on adiponectin production, but the size of the adipose tissue might be one of the key 
determinants of adiponectin levels.  
We found more than a two fold increase in HMW adiponectin level when compared with 
the total adiponectin level (17.3% vs. 8.2%). We also found highly significant associations 
between total and HMW adiponectin at baseline and six months. Although we did not measure 
MMW and LMW adiponectin levels separately, it is possible that the increased total adiponectin 
level might have reflected largely the change in HMW adiponectin. Additionally, a comparable 
relationship between weight loss and both total and HMW adiponectin levels suggest that a 
measurement of only total adiponectin might be adequate to examine relationship between the 
two and that the role of HMW adiponectin level is no more important than that of total 
adiponectin in relation to weight loss.  
29 
The main limitation of this study included the self-reported diet measure. Additionally, 
dietary data collected with the 3-day Food Records may not represent dietary intake over six 
months. However, the interventionists reviewed the diaries to provide feedback and confirm that 
participants complied with the intervention protocol during the rest of the study period. 
Participants’ reporting of meat products in the 3-day Food Records was consistent with what 
they had reported in the weekly diaries. Hence, we considered the reporting of meat, poultry and 
fish in the LOV-D group to be reliable indicators of adherence to the LOV-D. Moreover, we did 
a separate analysis with only those who were 100% adherent to LOV-D group and found no 
difference, thus it unlikely that bias related to adherence to the LOV-D was present. The small 
representation of males is another limitation. The strengths of this study included the prospective 
measurement of both total and HMW adiponectin levels and a comprehensive examination of the 
effects of diet and weight loss on adiponectin levels with a relatively large sample size for a 
considerably longer period than reported in the literature. Additionally, data were obtained from 
a randomized clinical trial.  
3.6    CONCLUSION 
 
The study showed the beneficial effects of the intervention on changes in adiponectin levels in 
both diet groups. These findings suggest that weight loss is associated with improved total and 
HMW adiponectin levels; however they are independent of the diet type. Moreover, a weight 
loss closer to 10% might be necessary for significant improvements in adiponectin levels. Thus, 
focusing on enhancing weight loss might be the better approach to improving adiponectin levels. 
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Table 3-1 Baseline characteristics by the dietary groups (N = 143) 
 
Variables STD-D 
(n = 79) 
LOV-D 
(n = 64) 
P* value 
Age (y) 43.5 ± 8.82 45.2 ± 8.1 .22 
Female [n (%)] 71 (89%) 56 (88%) .79 
Education (y) 15.4  ± 2.5 15.2 ± 2.4 .67 
White [n (%)] 53 (67%) 43 (67%) .84 
Weight (kg) 94.7 ± 15.1 93.7 ± 12.9 .67 
BMI (kg/m2) 33.6 ± 4.1 34.0 ± 3.9 .58 
Total cholesterol (mg/dL) 201.8 ± 35.3 203.8 ± 40.4 .76 
HDL cholesterol (mg/dL) 54.3 ± 11.7 50.7 ± 10.5 .06 
 LDL cholesterol (mg/dL) 121.7  ± 33.0 126.1 ± 36.0 .43 
Triglycerides (mg/dL) 129.4 ± 74.2 134.8 ± 65.3 .65 
Energy intake (kcal) 2011.6 ± 565.9 2079.1 ± 677.1 .52 
Total fat (% kcal) 34.8 ± 6.4 34.9 ± 6.9 .90 
Carbohydrate (% kcal) 49.4 ± 8.1 50.4 ± 7.2 .42 
Protein (% kcal) 16.0 ± 3.6 15.6 ± 3.6 .56 
Animal protein (% kcal) 11.2 ± 3.4 10.1 ± 3.5 .15 
Energy expenditure (kcal/wk) 2103.6 ± 2054.0 2218 ± 2167 .32 
Total adiponectin (ug/ml) 7.8 ± 3.7 7.6 ± 2.8 .72 
HMW adiponectin (ug/ml) 3.3 ± 2.2 3.2 ± 1.6 .81 
 
Note, Data are expressed as mean ± SD (except gender). 
STD-D = standard weight loss diet; LOV-D = lacto-ovo-vegetarian diet; BMI = body mass 
index; HDL = high-density lipoprotein; LDL = low-density lipoprotein; HMW = high molecular 
weight. 
*p-values are from two sample t-test or Chi-square test. 
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Table 3-2 Change and percent change score at six months by the dietary groups (N = 143) 
 
 STD-D (n = 79) LOV-D  (n = 64) p* value 
 Change Percent change Change Percent change 
Weight (kg) -8.0 ± 6.62 -8.5 ± 6.3 -8.3 ± 6.0 -9.0 ± 6.0 .80 
BMI (kg/m2) -2.8 ± 2.1 -8.4 ± 6.3 -3.0 ± 2.0 -9.0 ± 5.9 .51 
Total cholesterol (mg/dL) -3.0 ± 26.6 -.4 ± 13.6 -9.4 ± 28.1 -3.7 ± 12.7 .17 
HDL cholesterol (mg/dL) -2.8 ± 7.5 -4.1 ± 13.3 -2.0  ± 7.9 -2.3 ± 15.6 .56 
 LDL cholesterol (mg/dL) 3.2 ± 23.0 3.2 ± 18.9 -6.8 ± 22.8 -3.2 ± 15.7 .06 
Triglycerides (mg/dL) -17.3 ± 58.07 -4.7 ± 30.8 -2.6 ± 64.8 -2.8 ± 20.6 .15 
Energy intake (kcal) -602.2 ± 508.1 -26.9 ± 21.5 -674.2 ± 497.5 -29.2 ±17.1 .47 
Total fat (% kcal) -9.4 ± 8.9 -25.3 ±23.5 -11.3 ± 9.6 -29.5 ± 26.5 .31 
Carbohydrate (% kcal) + 7.3 ±  10.9 +17.6 ±  25.7 +13.0 ± 10.5 +28.2 ± 24.5 .01 
Total protein (% kcal) +2.8 ± 4.6 +22.1 ± 42.7 -0.1 ± 4.5 -3.7 ± 33.7 .0006 
Animal protein (% kcal) + 1.1 ± 4.8 +18.8 ± 66.1 -3.6 ± 4.7 -28.2 ± 46.1 <.0001 
Energy expenditure (cal/wk) + 1298 ± 2908 + 348 ± 874 + 1249 ± 2812 + 243 ± 420 .98 
Total adiponectin (ug/ml) + .4 ± 1.4 + 7.2 ± 17.8 + .6 ± 1.8 + 9.4 ± 21.8 .45 
HMW adiponectin (ug/ml) + 0.3 ± 0.9 + 18.5 ± 32.9 + 0.3 ± 1.0 + 15.8 ± 34.5 .83 
 
     Note, Data are expressed as mean ± SD 
STD-D = standard weight loss diet; LOV-D = lacto-ovo-vegetarian diet; BMI = body mass index; HDL = high-density lipoprotein;               
LDL = low-density lipoprotein; HMW = high molecular weight 
    *p-values are from two sample t-test or or Mann-Whitney test 
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Table 3-3 Final multiple regression models on changes in adiponectin levels at six months (N = 143) 
 
 
   
Note, Reference groups = males, White and standard calorie and fat restricted diet  
Δ = change; HMW = high molecular weight 
 
Measures Total adiponectin Δ (%) HMW adiponectin Δ (%) 
 Estimate s.e. p value Estimate s.e. p value 
Age (y) 0.64 0.19 .73 0.02 0.32 .94 
Gender -7.96 5.49 .14 -18.03 9.24 .06 
Race 0.25 0.26 .3 -0.02 0.15 .8 
Diet groups 1.51 3.23 .64 -3.80 5.40 .48 
Weight Δ (%) -0.71 0.27 .01 -1.37 0.47 .004 
Baseline weight (kg) 0.02 0.05 .65 0.06 0.09 .50 
Energy expenditure Δ (%) 0.0008 0.0006 .20 0.0003 0.001 .76 
Baseline energy 
expenditure (cal/wk) 
0.0007 0.0008 .41 -0.0003 0.001 .79 
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Figure 3-1 Effect of the level of weight loss on changes in total and HMW  
adiponectin levels.  
HMW, high molecular weight 
* Indicates significant differences from the first quartile, P = < .05 
P-values are from one way ANOVA and tukey post hoc test.  
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4.1    ABSTRACT 
Background: To determine whether baseline levels or intervention-associated changes in total 
and high molecular weight (HMW) adiponectin levels were associated with insulin resistance 
after six months of behavioral treatment for weight loss.  
Design: An ancillary study to a behavioral weight loss trial; the intervention was delivered in 
group sessions.  
Methods: Participants included 143 overweight/obese adults with a mean body mass index of 
33.7 kg/m2. The sample was 88% female, 67% White and 44.2 ± 8.5 years old. We measured 
circulating adiponectin levels (total and HMW) and evaluated the homeostasis model assessment 
of insulin resistance (HOMA). 
Results: At baseline, we found significant inverse associations between total adiponectin and 
HOMA (P < 0.001) and between HMW adiponectin and HOMA (P < 0.001) independent of 
weight. From baseline to six months, there was 17% improvement in HOMA (P < 0.001), 8% 
increase in total adiponectin (P = 0.001), 17% increase in HMW adiponectin levels (P < 0.001) 
and 8.72% weight loss (P < 0.001). At six months, we found a significant inverse association 
between changes in total adiponectin and HOMA (P = 0.04) that was independent of baseline 
weight and weight loss. In contrast, the association between changes in HMW adiponectin and 
HOMA was attenuated after adjustment for weight loss.  
Conclusions: An increased level of total adiponectin was associated with improved insulin 
sensitivity regardless of baseline weight and weight loss. However, baseline total and HMW 
adiponectin levels were more strongly associated with HOMA than changes in these measures at 
six months. HMW adiponectin level was not related more closely to insulin resistance than total 
adiponectin level.  
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4.2    INTRODUCTION 
Adiponectin is one of the many hormones secreted by adipose tissue as the dipokines in the 
human body. Insulin resistance (IR) and obesity are both associated with lower plasma 
adiponectin concentrations17. Although obesity has long been recognized as a major risk factor 
for the development of insulin resistance and type 2 diabetes, the mechanism by which adipose 
tissue contributes to progression of IR and type 2 diabetes is not well understood. Improvements 
in IR, glucose uptake in skeletal muscles and hepatic fatty acid oxidation upon administration of 
adiponectin in animal studies suggest that adiponectin may provide a link between adiposity and 
IR and diabetes104.  
 A strong inverse relationship between adiponectin and IR has been reported in 
population cross-sectional studies77, 79, 105. Moreover, longitudinal data also suggest a relationship 
between lower adiponectin levels and the development of IR and diabetes.  In a study of Pima 
Indians, those with high adiponectin concentration were found to be at a lower risk of developing 
diabetes than those with a low concentration suggesting a potential role of adiponectin in the 
pathogenesis of diabetes9. Similarly, an inverse association between adiponectin and the risk for 
diabetes was reported among a large population of healthy women35, a middle-aged population 
cohort82, and adults with insulin-resistance75. Mather et al. reported baseline adiponectin as a 
better marker of diabetes prevention than changes in adiponectin levels over one year in the 
Diabetes Prevention Program (DPP)106. However, no association was found between adiponectin 
and IR despite improved insulin sensitivity in response to weight loss among obese women46, 
obese adults41 and insulin resistant adults who did not have  diabetes93. Because of the variations 
due to population, sample size, differences in baseline degree of insulin resistance and 
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adiponectin, the evidence provided by these studies on the relationship between IR and 
adiponectin in the presence of weight loss remains equivocal. 
Adiponectin exits in circulation as low molecular weight (LMW), medium molecular 
weight (MMW) and high molecular weight (HMW) forms17, 24. HMW adiponectin has been 
suggested to be the most active form of adiponectin and more closely associated with IR with an 
ability to enhance insulin action25, 26. However, a major limitation of many epidemiological and 
intervention studies is the measurement of only total adiponectin level. Thus, little is known 
about how the relationship between HMW adiponectin and IR might differ from the relationship 
between total adiponectin and IR. Hence, the aims of this study were to determine whether 
baseline levels or intervention-associated changes in total and HMW adiponectin levels were 
associated with IR after six months of a behavioral intervention for weight loss.  
4.3    METHODS 
4.3.1 Study Design 
This was an ancillary study to the PREFER (Paving the road to everlasting food and exercise 
routine) trial, an 18-month behavioral weight loss study designed to evaluate the effects of 
treatment preference (Preference-Yes vs. Preference-No) and two dietary treatment options 
(standard calorie restricted low fat diet (STD-D)  vs. lacto-ovo-vegetarian diet (LOV-D). 
Participants were randomly assigned first to one of the two preference conditions (yes or no). If 
assigned to the Preference-No condition, they were further randomly assigned to one of the two 
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diet conditions (STD-D or LOV-D). If assigned to Preference-Yes condition, they were assigned 
to the diet they indicated as preferred at screening.  
Although the PREFER trial randomized participants by treatment preference and diet for 
a four-group design, the present study was conducted as a single sample without regard to 
randomized diet or preference condition. The design, recruitment and randomization procedures 
for the PREFER trial have been described in detail elsewhere96. The study protocol was 
approved by the University of Pittsburgh Institutional Review Board; all participants provided 
written informed consent. The PREFER trial was conducted between 2000 and 2005, and 
unthawed aliquots of serum samples were stored at -800C in the Laboratory at the School of 
Nursing. The current analysis was limited to the 143 participants whose sera samples were 
available from baseline and 6-month assessments.  
4.3.2 Study Population 
The study population included adults between 18 and 55 years of age; had a body mass index 
(BMI) between 27 and 43 kg/m2 inclusively and had adequately completed a 5-day food diary at 
screening. Individuals were excluded if they had diabetes or a medical condition requiring 
physician supervision of diet or physical activity; were pregnant; participated in a behavioral or 
pharmacological weight-loss program in the last six months, reported alcohol intake of ≥ four  
drinks/day and reported abstention from eating meat, poultry, or fish in the past month.  
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4.3.3  Intervention 
All four treatment groups received the same standard behavioral intervention; the only difference 
between the diet groups was that the LOV-D participants were instructed to eliminate meat, 
poultry and fish form their diet by the sixth week of the program. Details of the intervention have 
been reported elsewhere96. In brief, all participants received a daily energy and fat gram goal 
based on gender and baseline body weight. For participants weighing less than 200 lbs, the 
prescribed total energy intake was 1200 kcal for women and 1500 kcal for men. For those 
weighing more than or equal to 200 lbs, the goal was 1500 kcal for women and 1800 kcal for 
men. The daily fat gram goal was 25% of the total energy intake. Participants were instructed to 
increase their physical activity gradually, primarily via walking, until they reached a goal of 150 
minutes by week six. The intervention group sessions were held weekly during the first six 
months. The cognitive-behavioral intervention used several strategies from conceptual models of 
motivation and behavior change. All participants received nutritional and behavioral counseling 
and were provided with practical hands-on experience to develop skills to implement a healthy 
lifestyle. All participants self-monitored their daily energy and fat intake, as well as the physical 
activity (duration and type) that they performed during the study period.  
4.3.4 Measures 
Baseline demographic characteristics were collected via a self-administered, standardized 
questionnaire. All anthropometric, biochemical and adiponectin measurements were obtained at 
baseline and six months. We measured weight on a digital scale (Tanita Corporation of America, 
Inc., IL) with the individual in light clothing and without shoes. Height was measured with a 
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wall-mounted stadiometer. Blood samples, obtained following a 12-hour fast were assayed at the 
Heinz Nutrition Laboratory, University of Pittsburgh. Plasma glucose was measured with the use 
of the hexokinase-glucose 6-phosphate dehydrogenase enzymatic assay (Sigma Diagnostics, St. 
Louis, MO) and insulin concentration was measured by a radioimmunoassay kit (Linco 
Research, St. Charles, MO). Insulin resistance was assessed by the homeostasis model 
assessment of insulin resistance (HOMA-IR) and was calculated as fasting insulin concentration 
(U/mL) x fasting glucose concentration (mmol/L)/ 22.5. Serum levels of total and HMW 
adiponectin were determined using the ELISA technique (ALPCO Diagnostics, Salem, NH). The 
intra-assay and inter-assay CVs were 6.4% and 12.7% for total adiponectin and 6.4% and 12.6% 
for HMW adiponectin, respectively. All samples were assayed in duplicate.   
4.3.5 Statistical Analysis 
Statistical analyses were performed using SAS (version 9.2; SAS Institute Inc, Cary, NC). All 
continuous variables were checked for normality. Basic statistics were expressed as mean ± SD 
or as proportions unless otherwise specified. For all continuous variables, comparisons between 
baseline and 6-month measures were examined using a paired Student’s t-test. A chi-square test 
was performed for comparing the categorical variables at baseline. Associations between 
continuous variables were assessed using the Pearson or Spearman correlation coefficient. 
Separate multiple linear regression models were used for HOMA at baseline and change in 
HOMA score (6-month – baseline scores) as the dependent variables to examine associations 
between total and HMW adiponectin at baseline and six months. The models were adjusted for 
age, gender, race, baseline weight, baseline energy expenditure, changes in weight and energy 
expenditure. All tests performed were two-sided and significance level was set at P < 0.05. 
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4.4    RESULTS 
Of the 176 participants randomized at baseline, 151 completed the 6-month assessment and the 
sera samples of 143 (95%) participants were available from both baseline and 6-month 
assessments. The majority of participants were female (88%), White (67%), currently married or 
living with a partner (65%) and employed (94%). The mean age was 44.2 ± 8.5 years old with a 
BMI range of 26.71 to 42.56 kg/m2 (Mean= 33.78 kg/m2) and, on average 15.3 years of formal 
education. No differences in baseline characteristics were found between participants who were 
excluded and those included in the analysis. 
 Table 1 describes the baseline, 6-month and change score measures. At baseline, HOMA 
did not differ by gender (female vs. male: 4.36 ± 2.23 vs. 4.97 ± 2.24; P = 0.3) or by race (white 
vs. non-white: 4.47 ± 2.34 vs. 4.33 ± 20.00; P = 0.7). However, females had significantly higher 
total (7.85 ± 3.32 vs. 6.31 ± 2.58 ug/ml; P = 0.04) and HMW adiponectin levels (3.37 ± 2.9 vs. 
2.39 ± 1.43 ug/ml; P = 0.03) than males. From baseline to 6 months, there was a 17% reduction 
in HOMA (P < 0.001), an 8% increase in total adiponectin (P = 0.001) and 17% increase in 
HMW adiponectin levels (P < 0.001). Further, there was a significant weight loss (8.72%) at six 
months (P < 0.001). We observed highly significant correlations between total and HMW 
adiponectin levels at baseline (r= 0.95; P < 0.001) and also at six months (r= 0.95; P < 0.001). At 
baseline and six months, weight, BMI, glucose, and insulin showed significant positive 
associations with the HOMA score while total and HMW adiponectin levels showed significant 
negative association with HOMA (P for all < 0.001).  
Separate multiple regression analyses were performed for both baseline and 6-month 
measures with baseline HOMA and the change in HOMA scores as the dependent variables, 
respectively. The final model with baseline measures adjusted for weight indicated significant 
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inverse associations between total adiponectin and the HOMA score (P < 0.001) and between 
HMW adiponectin and HOMA (P < 0.001). The estimates for total and HMW adiponectin  
remained highly significant after adjustment for baseline weight (Table 2). At six months, the 
final regression model revealed a significant inverse association between changes in total 
adiponectin and HOMA (P = 0.04) that was independent of baseline weight and weight loss. In 
contrast, higher HMW adiponectin was associated with increased HOMA score without weight 
loss in the model (P = 0.02), but the association was no longer significant after adjustment for 
weight loss (Table 3). Additional adjustment for energy expenditure at baseline and six months 
did not alter the results.  
4.5    DISCUSSION 
A better understanding of the extent of the association of adiponectin with IR in obesity might 
help clarify mechanisms of insulin sensitivity, which in turn, might be beneficial in identifying 
preventive approaches to enhance insulin sensitivity and thereby reduce the risk for developing 
diabetes. Our findings revealed that the higher baseline levels of total and HMW adiponectin 
levels were significantly associated with lower HOMA score, independent of body weight. At six 
months, there were significant reductions in the HOMA score and weight, which paralleled the 
improvements in total and HMW adiponectin levels. The increase in total adiponectin was 
inversely associated with a decrease in the HOMA score independent of baseline weight and 
weight change. However, the significant association between changes in HMW adiponectin level 
and the HOMA score was attenuated after adjustment for weight change.   
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We observed significant inverse associations of total and HMW adiponectin levels with 
the HOMA score at baseline even after adjusting for baseline weight indicating an independent 
association of total and HMW adiponectin levels with the HOMA score regardless of the degree 
of obesity. The association between total adiponectin and HOMA is consistent with findings 
from previous studies among individuals with type 2 diabetes6,  a representative community 
adult population77 and a community-based cohort with and without the metabolic syndrome79. 
The DPP study also reported an inverse association between baseline total adiponectin levels and 
future diabetes independent of baseline adiposity among individuals at increased risk for 
diabetes106. Our findings suggest the persistence of an independent role of not only total 
adiponectin but also HMW adiponectin levels in relation to IR among a generally healthy 
overweight/obese population with no diabetes or clinical vascular disease.  
We also examined the association between changes in total and HMW adiponectin levels 
and HOMA scores separately after six months of intervention. The degree of unadjusted 
association between HOMA and total and HMW adiponectin levels were similar at both baseline 
and six months. We observed intervention-associated significant reductions in weight, the 
HOMA score and improvements in total and HMW adiponectin levels. The increase in total and 
HMW adiponectin was associated with the change in weight suggesting that change in total and 
HMW adiponectin levels might reflect body weight change. The multiple regression analysis 
showed that an increased level of total adiponectin contributed to improved insulin sensitivity 
independent of baseline weight and change in weight. Although the estimate for change in total 
adiponectin decreased by 34% when change in weight was added to the model, these results 
indicate that improvements in total adiponectin level contributed to improved insulin sensitivity 
beyond the usual clinical markers of diabetes. The present study highlights the importance of 
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adiponectin in the development of IR and subsequent development of type 2 diabetes. Thus, 
interventions, such as the one used in this study, that target weight loss and increase total 
adiponectin levels may improve insulin sensitivity and reduce the risk of diabetes for overweight 
individuals.  
A few studies have reported HMW adiponectin to have a stronger association than total 
adiponectin level in the incidence of type 2 diabetes5, 81 and insulin sensitivity24-27. Most of these 
studies either had only a single measurement of HMW adiponectin level5, 26, 27, 81,were limited by 
the small sample size24, 25, 93, or had a pharmacological intervention107. We found a highly 
significant association between total and HMW at baseline. Bluher et al.108 reported no 
superiority of HMW adiponectin over total adiponectin values in predicting insulin sensitivity. 
Likewise, we also showed a similar magnitude of correlations between both total and HMW 
adiponectin levels with the HOMA score at baseline suggesting no clinical differences between 
total and HMW adiponectin levels in relation to insulin resistance.  
At six months, the significant association between changes in HMW adiponectin level 
and HOMA was attenuated after adjustment for change in weight and was no longer significant 
despite an increase in HMW adiponectin that was more than double the increase in total 
adiponectin. This finding indicates a possible threshold level of HMW adiponectin that might be 
needed to have an independent effect on change in the HOMA score. Alternatively, we cannot 
rule out the possibility of a different pathway of an intervention-associated change in HMW 
adiponectin level from the baseline HMW adiponectin level. Regardless of the mechanism, our 
study refutes the hypothesis of a predominant role of HMW adiponectin level over total 
adiponectin level in relation to IR. The study also provided us a unique opportunity to examine if 
baseline or intervention associated changes in total and HMW adiponectin levels were more 
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strongly associated with IR. We found that the degree of association between total and HMW 
adiponectin level were stronger at baseline than the relationship between changes in total 
adiponectin and the HOMA score at six months. Moreover, the significant association between 
change in HMW adiponectin level and HOMA score was taken over by weight loss. Consistent 
with the findings of Mather et al.106 we also found that the baseline total and HMW adiponectin 
levels were more closely related to IR than the changes in these measures at six months. 
The potential mechanism of how plasma adiponectin levels influence IR is still not 
known. A higher level of adiponectin level has been reported to increase fatty acid oxidation 
with subsequent reduction of triglycerides thereby directly sensitizing the body to insulin and 
reserving?? IR in animal models of obesity and diabetes109 and in humans27. Through in vitro 
studies, adiponectin has been shown to trigger the protein kinase, an insulin independent enzyme 
known to stimulate glucose use and increase fatty acid oxidation in skeletal muscle104. It has 
been reported that some inflammatory markers, such as tumor necrosis factor-α, interleukin-6 or 
C-reactive protein have an adiponectin inhibitory effect, which in turn may lead to IR105, 110. It is 
possible that the levels of these markers decrease with the corresponding increase in adiponectin 
levels with weight loss and may improve insulin sensitivity.  
A main limitation of the study included a measure of IR with a surrogate marker. 
However, HOMA derived from the mathematical model has been shown to be an adequate 
indicator of IR and has been used in many epidemiological and clinical studies. Also, the 
generalizability of these findings may be limited due to the relatively homogenous study 
population; however, the minority representation exceeded that of the local community. The 
strengths of the study included the measurements of both total and HMW adiponectin. An 
additional strength was its longitudinal design and examination of the relationship between total 
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and HMW adiponectin levels with IR cross-sectionally and prospectively. Moreover, the clinical 
measures were obtained via a standardized protocol and assays were performed with good 
precision and the study included a larger sample than what has been reported in the literature. 
4.6    CONCLUSION 
An increased level of total adiponectin contributed to improved insulin sensitivity regardless of 
baseline weight and weight loss. However, the association of change in total adiponectin and 
HOMA score was modest compared to baseline measures suggesting that the cross-sectional 
measure of total adiponectin might be a comparable indicator of IR and subsequent risk of 
developing diabetes among overweight or obese adults.  These findings provide support for the 
importance of adiponectin levels and a need for their improvements to prevent diabetes.  Thus, 
interventions that enhance adiponectin secretion or action may have potential for diabetes risk 
reduction. Improvements in the HMW adiponectin level were largely explained by the weight 
loss suggesting the role of HMW adiponectin level is no more important than that of total 
adiponectin in relation to improved insulin sensitivity.  
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Table 4-1 Baseline, six months and percent change scores in measures (N = 143) 
 
 Baseline 
means ± SD 
6-mo 
means ± SD 
6-mo % change 
means ± SD 
P1 
Weight (kg) 94.26 ± 14.10 86.10 ± 14.45 -8.16 ± 60.05 < 0.0001 
BMI (kg/m2) 33.78 ± 40.04 30.88 ± 4.54 -2.91 ± 20.01 < 0.0001 
Glucose (mg/dl) 96.13 ± 8.32 95.41 ± 8.35 -0.73 ± 8.67 0.31 
Insulin (uU/mg) 18.42 ± 8.35 14.23 ± 5.96 -4.18 ± 5.88 < 0.0001 
HOMA 4.43 ± 2.23 3.40 ± 1.58 -10.03 ± 1.64 < 0.0001 
Adiponectin (ug/ml) 7.68 ± 3.27 8.11 ± 3.13 0.44 ± 1.58 0.0013 
HMW (ug/ml) 3.26 ± 1.96 3.58 ± 1.90 0.32 ± 0.93 < 0.0001 
 
Note, BMI, body mass index; HOMA, homoeostasis model assessment of insulin resistance; 
HMW, high molecular weight. 
1significantly different at six months from baseline measures. 
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Table 4-2 Multiple regression models of total and HMW adiponectin levels on baseline HOMA measure (N = 143) 
 
Models Baseline HOMA R2 Models Baseline HOMA R2 
Estimate s.e. P Estimate s.e. P 
Model 1 
   Adiponectin (ug/ml) 
 
-0.28 
 
0.05 
 
< 0.001 
 
0.17 
Model 1 
   HMW (ug/ml) 
 
-0.42 
 
0.09 
 
< 0.001 
 
0.14 
Model 2  
   Adiponectin (ug/ml) 
   Gender 
   Race 
   Age (y) 
 
-0.29 
-0.12 
-0.40 
-0.02 
 
0.05 
0.55 
0.37 
0.02 
 
< 0.001 
0.83 
0.28 
0.27 
 
0.18 
Model 2 
   HMW (ug/ml) 
   Gender 
   Race 
   Age (yr) 
 
-0.45 
-0.10 
-0.52 
0.01 
 
0.09 
0.56 
0.38 
0.02 
 
< 0.001 
0.85 
0.17 
0.40 
 
0.15 
Model 3 
   Adiponectin (ug/ml) 
   Gender 
   Race 
   Age (y) 
   Weight (kg)  
 
-0.26 
0.45 
-0.46 
0.02 
0.06 
 
0.05 
0.34 
0.01 
0.02 
0.01 
 
< 0.001 
0.39 
0.18 
0.20 
< 0.001 
 
0.30 
Model 3 
    HMW (ug/ml) 
    Gender 
    Race 
    Age (yr) 
    Weight (kg) 
 
-0.38 
0.44 
0.55 
0.02 
0.06 
 
0.09 
0.54 
0.36 
0.02 
0.01 
 
< 0.001 
0.42 
0.12 
0.32 
< 0.001 
 
0.27 
 
Note, HMW, high molecular weight; HOMA, homoeostasis model assessment of insulin resistance. 
 Reference groups: gender-males, race- White  
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    Table 4-3 Multiple regression models of total and HMW adiponectin levels on change in HOMA at six months (N= 143) 
 
Models Change in  HOMA 
R2 
Models Change in  HOMA 
R2 Estimate s.e. P Estimate s.e. P 
 
Model 1 
   Adiponectin Δ (ug/ml) 
 
 
-0.25 
 
 
0.09 
 
 
0.004 
 
 
.06 
Model 1 
   HMW Δ (ug/ml) 
 
 
-0.34 
 
 
0.14 
 
 
0.02 
 
 
0.04 
 
Model 2  
   Adiponectin Δ (ug/ml) 
   Gender 
   Race 
   Age (y) 
 
 
-0.25 
0.95 
0.38 
0.01 
 
 
0.08 
0.43 
0.29 
0.01 
 
 
0.005 
0.03 
0.20 
0.9 
 
 
0.11 
Model 2  
   HMW Δ (ug/ml) 
   Gender 
    Race 
    Age (y) 
 
 
-0.32 
0.99 
0.33 
0.0003 
 
 
0.15 
0.43 
0.30 
0.01 
 
 
0.03 
0.02 
0.28 
0.98 
 
 
0.09 
 
Model 3 
   Adiponectin Δ (ug/ml) 
   Gender 
   Race 
    Age (y) 
   Baseline weight (kg)  
 
 
-0.26 
0.64 
0.44 
-0.000 
-0.03 
 
 
0.09 
0.43 
0.29 
0.02 
0.009 
 
 
0.003 
0.14 
0.13 
0.97 
0.003 
 
 
0.16 
Model 3 
   HMW Δ (ug/ml) 
   Gender 
   Race 
   Age (y) 
   Baseline weight (kg)  
 
 
-0.34 
0.68 
0.38 
-0.001 
-0.03 
 
 
0.15 
0.44 
0.29 
0.02 
0.009 
 
 
0.02 
0.12 
0.19 
0.92 
0.003 
 
 
 
0.14 
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Table 4-4 Contd.         
Models Change in  HOMA 
R2 
Models Change in  HOMA 
R2 Estimate s.e. P Estimate s.e. P 
 
Model 4 
   Adiponectin Δ (ug/ml) 
   Gender 
   Race 
   Age (y) 
   Baseline weight (kg) 
   Weight Δ (kg) 
 
 
-0.17 
0.06 
0.46 
0.0005 
-0.03 
0.10 
 
 
0.08 
0.42 
0.27 
0.01 
0.009 
0.02 
 
 
0.04 
0.88 
0.09 
0.97 
0.005 
< 0.0001 
 
 
0.27 
Model 4 
   HMW Δ (ug/ml) 
   Gender 
   Race 
   Age (y) 
   Baseline weight (kg) 
   Weight Δ (kg) 
 
 
-0.18 
0.10 
0.40 
0.000 
-0.02 
0.10 
 
 
0.14 
0.48 
0.27 
0.01 
0.008 
0.02 
 
 
0.21 
0.82 
0.14 
0.99 
0.006 
< 0.0001 
 
 
0.26 
 
Note, HMW, high molecular weight; HOMA, homoeostasis model assessment of insulin resistance; Δ, change. 
Changes values were defined as six months – baseline.  
Reference groups: gender-males, race- White 
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5.1    ABSTRACT 
Objectives:  The study assessed the longitudinal relationships between weight, waist 
circumference, body composition and adiponectin levels at six and 12 months of a behavioral 
intervention for weight loss. 
Methods and Results: The sample included 133 overweight/obese adults with a mean BMI of 
33.4 ± 4.7 kg/m2 and was 86% female, 81% White, and was on average, 45.3 ± 8.8 years old. We 
measured circulating adiponectin level, weight, waist circumference and body composition at 
baseline, six and 12 months. Retention at six months was 91% and 85% at 12 months. 
Adiponectin level increased by  23.4% and 20.1% relative to the baseline value at six and 12 
months, respectively (P<0.0001). There were significant reductions in weight (-6.79 ± 6.39%), 
waist circumference (-6.33 ± 5.93%) and percent body fat (-5.29 ± 9.70%) at six months (Ps for 
all <0.0001) with no significant differences between six and 12 months. Significant effects of 
weight loss and reductions in BMI, waist circumference and body fat were found on increased 
adiponectin levels over time (Ps for all <0.002) However, no associations were observed 
between changes in fat free mass with adiponectin levels over time.  
Conclusions: Reductions in body weight, BMI, waist circumference, and percent body were 
strongly associated with increases in adiponectin levels over time. Interventions that target a long 
term weight loss help enhance adiponectin levels.   
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5.2    INTRODUCTION 
Obesity is a disorder characterized by chronic mild inflammation in addition to its association 
with cardiovascular disease, insulin sensitivity and diabetes. Adiponectin is one of the many 
adipokines secreted by the adipose tissue that may act as an anti inflammatory protein with some 
protection against diabetes and atherosclerosis. A number of studies have reported decreased 
adiponectin level in obese individuals with higher body mass index (BMI) when compared to 
normal weight individuals7, 8, 111. Several intervention studies have described significant 
improvement in adiponectin level with diet or lifestyle induced weight loss57, 64, 92 while others 
failed to find such improvement in spite of significant weight loss41, 49-52, 56.  
A strong inverse relationship of visceral adipose tissue (VAT) and body fat mass with 
adiponectin has been reported in population studies111,112. Similarly, an inverse association 
between waist circumference and adiponectin has also been reported 19, 111. However, a major 
limitation of these studies was the cross-sectional design. Recently, a study by Okauchi et al.113 
found improvement in adiponectin level with reductions in BMI, waist circumference and 
visceral fat accumulation among middle aged individuals in the general population. No previous 
studies have reported longitudinal relationships between weight loss and adiponectin levels using 
repeated assessments among overweight/obese individuals. Hence, the aims of this study were to 
assess the longitudinal relationships of weight, waist circumference and body composition with 
adiponectin levels at six and 12 months of participation in a randomized clinical trial that 
included a behavioral intervention for weight loss. 
 
 
 
54 
5.3    METHODS 
5.3.1 Study Design and Population 
This was a secondary analysis of the 6- and 12-month data from the Self-Monitoring and 
Recording with Technology (SMART) weight loss trial. SMART was a 24-month randomized 
clinical trial designed to determine the effects of different methods of self-monitoring on weight 
loss in which participants were randomized to using one of the three self-monitoring methods: 
paper diary, or personal digital assistant (PDA), or PDA with the same software plus a tailored 
feedback program. The study protocol was approved by the University of Pittsburgh Institutional 
Review Board.  All participants provided written informed consent. 
The design, recruitment and randomization procedures for the SMART trial have been 
described in detail elsewhere114. In brief, the study recruited three cohorts of individuals from the 
community between 2006 and 2008 for a total of 210 participants. Individuals were eligible to 
participate if they were between 18 and 59 years old with a BMI between 27 and 43 kg/m2 and 
were able to record in a 5-day food diary at screening. Study exclusion criteria included 
pregnancy, individuals with conditions that required medical supervision of diet or exercise and 
those who participated in a weight-loss program in the six months prior to recruitment or planned 
an extended vacation or relocation during the study period. The current analysis was limited to 
133 participants from the first and second cohorts of the SMART trial whose sera samples were 
available from baseline assessment and the analysis was conducted as a single sample without 
regard to randomized treatment condition.  
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5.3.2 Intervention 
All three treatment groups received the same standard behavioral intervention; the only 
difference was in the self-monitoring method they were assigned to use. Details of the 
intervention have been reported elsewhere114. The intervention during the 12 months was 
delivered in 16 weekly and 16 bi-weekly group sessions. The sessions were held separately for 
the three treatment groups and the same multidisciplinary team (behavioral scientist, nutritionist 
and exercise specialist) led the sessions. All participants received nutritional and behavioral 
counseling and were provided with practical hands-on experience to develop skills to implement 
a healthy lifestyle. All participants received a daily calorie and fat gram goal based on gender 
and baseline body weight. For participants weighing less than 200 lbs, the prescribed daily total 
calorie intake was 1200 kcal for women and 1500 kcal for men. For those weighing more than or 
equal to 200 lbs, the goal was 1500 kcal for women and 1800 kcal for men. The daily fat gram 
goal was 25% of the total daily calories for everyone. Participants were instructed to reach a 
weekly goal of 150 minutes of moderate intensity exercise by sixth week and 180 minutes by the 
24th week (six months). They were also instructed to add three 30-minute resistance exercise 
sessions per week at six months. All participants self-monitored their daily energy and fat intake, 
as well as physical activity (duration and type) during the study period.  
5.3.3 Measures 
Demographics. Baseline demographic characteristics were collected via a self-administered, 
standardized questionnaire. Information obtained included age, gender, race, marital status, 
education and income.  
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Anthropometric measurements. All measures were obtained at baseline and repeated at six and 
12 months after an overnight fast. A Tanita scale and body fat analyzer (Tanita Corporation of 
America, Inc., Illinois, USA) was used for weight and body composition. Body composition was 
assessed via bioelectrical impedance analysis (BIA). Foot to foot BIA was conducted using the 
Tanita and participants were measured standing erect with bare feet on the analyzer footpads. 
Height was measured on a wall-mounted standiometer. BMI was computed using the following 
formula:  BMI = weight (kg) /height (meters2). Waist circumference was measured at least twice 
with a Gulick II measuring tape. The tape was placed around the bare abdomen just above the 
hip bone and the measurement was taken after breathing out normally. When two measurements 
were obtained that were within two cm of each other, the average of the two measurements was 
used.   
Adiponectin measures. Blood samples were obtained following a 12-hour fast.  Sera from each 
assessment point were stored at -80oC at the laboratory at School of Nursing. Serum level of total 
adiponectin was determined using the ELISA kit (Millipore, Billerica, MA). All samples were 
assayed in duplicate. The analyses were performed at the R. Tracy Laboratory, University of 
Vermont.  
5.3.4 Statistical Analysis 
All continuous variables were checked for normality. Basic statistics were expressed as mean ± 
SD for continuous variables and as proportions for categorical variables unless otherwise 
specified. Differences in baseline adiponectin value by gender, race, smoking status and 
medication use were examined with a two sample Student t-test. For all the studied variables, the 
changes from baseline to each time point were expressed as scores (Δ = 6 or 12 months - 
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baseline) and the changes between six and 12 months were expressed as scores (Δ = 12 months - 
6 months). To investigate relationships of changes in weight, BMI, waist circumference and 
body composition (percent body fat, fat free mass) with changes in adiponectin level, we applied 
repeated-measures analysis using linear mixed effects modeling via PROC MIXED in SAS. The 
unadjusted models included the main effects for changes in weight, BMI, waist circumference, 
body composition, time and their interaction. Five possible interactions were tested (Δ weight 
and time; Δ BMI and time; Δ waist circumference and time; Δ percent fat and time; Δ FFM and 
time) and included in the final model only if found to be statistically significant. Separate models 
were conducted for each physical measure. The adjusted models included age, gender, ethnicity, 
baseline adiponectin level and each baseline physical measure. Additional adjustment included 
smoking status.  
Although 133 sera samples were available from baseline assessment, mixed model 
analyses were performed on 122 participants who had at least one measure of adiponectin level 
at either the six or 12 months assessment. Data from 122 participants were used regardless of 
their participation in all three assessments.  Models were based on 206 observations across the 
assessments. Physical measurements and adiponectin values were missing for some participants; 
the missing data were mainly due to participant attrition and unavailability of stored sera samples 
that happened at different time points during the study. Thus, it was assumed that these data were 
missing at random. Based on the Akaike Information Criterion (AIC) and Bayesian Information 
Criterion (BIC), unstructured covariance structures were used to fit the model. The restricted 
maximum likelihood algorithm was used in all the models. Sensitivity analyses were conducted 
for outliers identified through graphical methods. When outliers were omitted via sensitivity 
analysis, the results did not change, supporting the robustness of our findings. All tests 
58 
performed were two-sided and significance level was set at P < 0.05.  Statistical analyses were 
performed using SAS (version 9.2; SAS Institute Inc, Cary, NC). 
5.4 RESULTS 
Overall, sera samples of 133 (98%) of the 136 participants who completed the baseline 
assessment were available. For this secondary analysis, the retention was at 91% followed by 
85% at 6 and 12 months. The sample was 86% female, 81% White, and 45.29 ± 9.76 years old 
with BMI of 34.68 ± 4.65kg/m2 and on average completed 15.53 ± 3.01 years of formal 
education. Thirty participants (23%) were overweight and 103 were obese (77%) according to 
the criteria set by the World Health Organization. The proportion of current smokers was 10% 
(n=13). The number of participants taking medication for high cholesterol was 17 (13%) at 
baseline and remained 15 (11%) at 6 and 12 months. We found no differences in baseline 
adiponectin level by gender (male: 14.36 ± 8.88 vs. female: 13.90 ± 6.95 ug/ml; P = 0.81), race 
(White: 14.20 ± 7.36 vs. nonwhite: 13.12 ± 6.58 ug/ml; P = 0.50), smoking status (current 
smokers: 11.62 ± 5.30 vs. non smokers 14.26 ± 7.35 ug/ml; P = 0.21) and medication use for 
high cholesterol (medication users: 13.90 ± 6.95 vs. medication non-users 14.95 ± 7.82 ug/ml; P 
= 0.5). 
Table 1 shows the descriptive values of all studied variables at each time point (baseline, 
six and 12 months). Increase in mean adiponectin level was 23.43% and 20.11% at six months 
and 12 months, respectively, relative to the baseline value (P <0.0001) with no significant 
difference between changes at six and 12 months. There were significant reductions in weight (-
6.79 ± 6.39%), BMI (-6.59 ± 6.39%), waist circumference (-6.33 ± 5.93%), percent body fat (-
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5.29 ± 9.70%) and fat free mass (FFM) (- 2.94 ± 5.42%) at 6 months (Ps for all <0.001). 
Changes in weight and reduction in BMI, waist circumference and body composition were not 
significant between six and 12 months. 
In the longitudinal analysis with adiponectin at six and 12 months as the dependent 
variable, we found no significant interactions between time and changes in weight (F = 0.16; P = 
0.69), BMI (F = 0.19; P = 0.66), waist circumference (F = 0.02; P = 0.88), percent body fat (F = 
0.22; P = 0.63), FFM (F = 0.46; P = 0.50). The model with changes in weight adjusted for time, 
age, gender and race indicated a significant increase in adiponectin levels over 12 months with 
weight loss (β(s e) = -0.15(0.05), F = 9.30;   P = 0.002) (Tables 2 and 7). When the model was 
replaced with changes in BMI substituting for weight, the association between changes in BMI 
and adiponectin levels over time remained significant (β(se) = -0.39(0.13), F = 8.67; P = 0.003) 
(Tables 3 and 7).  
Significant associations were observed between reduction in waist circumference (β(se) = 
-0.13(0.05), F = 7.68;  P = 0.006) (Tables 4 and 7)  and percent body fat (β(se) = -0.21 (0.07), F 
=  9.29; P = 0.002) (Tables 5 and 7) and increased adiponectin levels over time in the separate 
models adjusted for age, race and gender. However, no such significant association was found 
between changes in FFM and adiponectin levels over time (β(se) = -0.01(0.04), F = 0.00; P  = 
0.76) (Tables 6 and 7). Additional adjustment for baseline smoking status in all the models with 
each physical measure did not alter the results (Tables 2-7).  
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5.5 DISCUSSION 
Participants in the 12-month behavioral intervention for weight loss experienced significant 
reductions in weight, waist circumference and body fat, which were paralleled with increased 
adiponectin levels. We observed a significant increase in adiponectin levels over time with 
reductions in weight, BMI, waist circumference, and body fat; no such association was found 
between changes in FFM and adiponectin levels suggesting adipose tissue as the source of 
adiponectin levels and a negative feedback mechanism of obesity on adiponectin production.  
The maximum reduction in weight, BMI, and waist circumference and greatest 
improvement in adiponectin level occurred during the first six months followed by maintenance 
of these measures during the second six months; similar patterns of changes in weight and BMI 
have been reported in previous studies 115, 116. Despite recommending participants to add 
resistance exercise to attenuate fat-free tissue loss and increase strength and function, we 
observed significant reduction in FFM at six months, which was maintained at 12 months.  
Dixon et al. 117 reported the expected ratio of fat-free mass loss to fat mass loss is 1.34 during 
intentional weight loss among adults. In our study this ratio was 1.41; more favorable than the 
expected ratio. As suggested by Heymsfield et al., 118 this study adds to the evidence that an 
intentional weight loss also reflects the loss of body protein in addition to body fat loss. 
However, the loss of body protein may diminish in magnitude over time.  
Our study demonstrated a significant association between increased adiponectin levels 
and a reduction in body fat during a 12-month intervention for weight loss. In contrast, changes 
in FFM showed no association with changes in adiponectin. Our findings of a significant 
negative association between adiponectin and body fat have been reported in cross-sectional 
studies 6, 111, 119, 120. The non-significant findings between FFM and adiponectin found in the 
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study strongly suggest that the secretion of adiponectin is not regulated by FFM but rather by the 
negative feedback of obesity on adiponectin production.  As suggested by  Weyer et al.6 and 
Haval et al.121, the size of the adipose tissue might also be one of the key determinants of 
adiponectin level. These cumulative results provide further evidence that the production and 
secretion of adiponectin is modified by the amount and size of adipose tissue. 
We also examined the relationships between changes in waist circumference, weight and 
BMI with adiponectin level and found that a reduction in waist circumference, weight and BMI 
was associated with improvement in adiponectin level over time. Several cross-sectional studies 
have reported a negative association between waist circumference and adiponectin levels 66, 111, 
122. We confirmed these findings in this longitudinal study using repeated measures. Although 
our measure of body composition with BIA did not differentiate between visceral and 
subcutaneous adipocytes, it has been known that central fat, as measured by waist circumference 
is considered a surrogate marker for visceral adipocytes 123. In a cross-sectional study, Nakamura 
et al.124 reported an inverse association between visceral adipocytes and adiponectin. Recently, 
evidence indicating abdominal adiposity is more strongly associated with diabetes and heart 
disease than overall adiposity measured by BMI or weight is accumulating 125-127.  Kanaya et 
al.128 reported increased risk of diabetes with increasing level of visceral fat among the Health 
ABC study participants. Similarly, adverse metabolic risk profiles have also been reported with 
an increasing proportion of visceral adipose tissue 129, 130. Hence, associations between visceral 
adipose tissue and diabetes or cardiovascular diseases reported in previous studies may be partly 
explained by the negative association between changes in waist circumference and adiponectin 
level. Our findings from this longitudinal study provide data to suggest that adiponectin might be 
one of the many links between obesity, diabetes and CVD.  
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A potential biological mechanism of how adiponectin influences diabetes and heart 
disease is still not known. The findings of our study suggest reduced adiponectin level with 
increasing adiposity, in particular body fat and central adiposity. It has been hypothesized that 
the increased release of pro-inflammatory cytokines from adipose tissue with reduced secretion 
of anti-inflammatory adipokines, such as adiponectin, can generate a low grade chronic 
inflammatory state. This imbalance of pro- and anti- inflammatory markers might play a role in 
the future development of diabetes and cardiovascular diseases through reduced insulin 
sensitivity and endothelial dysfunction. Lifestyle factors such as over eating and physical 
inactivity induce fat accumulation, which results in dysfunction of adipose tissues. Hence, 
current findings also emphasize the importance of focusing on long term weight loss 
accompanied by reduction of total body fat loss and central obesity as an essential preventive 
measure for optimal health.  
We used BIA using Tanita to evaluate body composition in the present study, which is 
not considered the gold standard. However, significant correlations between measurements 
obtained from Tanita and dual-energy x-ray absorptiometry and under water weighing have been 
reported131. Recently, Sai Krupa Da132 reported accuracy and reliability of measuring body 
composition with BIA and suggested its application as a screening tool in clinical practice and in 
population based research. Moreover, we standardized measurement conditions to an overnight 
fast and normal levels of hydration for each measurement, thus we feel confident that the 
prediction error of the BIA method was at ≤ 4%133.  The relatively homogenous study population 
might have limited the generalizability of our findings; however, 22% minority in the study 
sample represents the regional population. Another important limitation was a 15% male 
representation. The study population presented in this study represents the gender composition of 
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individuals seeking weight loss treatment as the proportion of males is similar to what has been 
reported by other weight loss studies134-136.  
The main strength of the study was that it was the first study to include the repeated 
measures of both adiponectin level and physical measures and examine their relationships over 
time. Moreover, the clinical measures were obtained via a standardized protocol and assays were 
performed with good precision and the study included a larger sample than what has been 
reported in the intervention studies. An additional strength was our 91% retention rate at 6 
months and 85% retention at 12 months, which was comparable or better than rates reported for 
other weight-loss studies. 
5.6 CONCLUSION 
In conclusion, changes in body composition continuously affected the level of adiponectin over 
time. We observed beneficial effects of the behavioral intervention on improvement in 
adiponectin level with reductions in weight, waist circumference and percent body fat. 
Reductions in weight, BMI, waist circumference, and body fat increased adiponectin levels. As 
adipose tissue might be the key determinant in the secretion of adiponectin, interventions such as 
behavioral weight loss interventions accompanied by total fat loss and reduced central obesity 
may enhance serum adiponectin levels. 
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Table 5-1 Physical measures and adiponectin level at baseline, six and 12 months 
 
Measures Baseline (N=133) 6 months (n=121) 12 months (n=113) 
 
Mean ± SD (min, max) Mean ± SD (min, max) Mean ± SD (min, max) 
Weight (kg) 94.38 ± 15.87 (66.36, 143.27) 88.61 ± 16.28 (56.18,138.45) 88.28 ± 17.17 (54.64, 135.82) 
BMI (Kg/m2) 34.35 ± 4.69 (26.53, 44.53) 32.22 ± 5.01 (21.69, 43.84) 32.10 ± 5.27 (221.09, 44.12) 
WC (cm) 106.17 ± 13.01 (78.75, 138.75) 99.83 ± 13.79 (68.50, 138.50) 100.10 ± 13.69 (67.00, 138.25) 
Body fat (%) 42.66 ± 5.86 (20.40, 52.60) 40.37 ± 7.45 (19.30, 54.00) 39.84  ± 7.84 (18.20, 63.10) 
Fat free mss (kg) 53.35 ± 9.22 (39.91, 84.23) 51.78 ± 8.72 (39.82, 80.18) 51.75 ± 9.2 (40.27, 79.28) 
Adiponectin (ug/ml) 14.00  ± 7.20 (2.42, 48.05) 16.21  ± 7.42(4.24, 44.85) 16.47  ± 7.81 (4.45, 46.54) 
 
Note, BMI, body mass index; WC, waist circumference 
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Table 5-2 Relationships between changes in weight and adiponectin: mixed models  
 
 F vaule P value 
 
Model 1    Weight Δ (kg) 
 
2.46 
 
0.11 
                 Time  1.15 0.31 
                  Weight Δ *time 0.51 0.60 
 
Model 2    Weight Δ (kg) 
 
9.30 
 
0.002 
      Baseline weight (kg) 0.01 0.90 
      Baselineadiponectin (ug/ml) 516.28 <0.0001 
Time 0.01 0.93 
Age 3.11 0.08 
                 Gender 1.78 0.18 
                 Race 0.02 0.87 
 
Model 3    Weight Δ (kg) 
 
9.08 
 
0.003 
Time 0.01 0.91 
Baseline weight (kg) 0.07 0.79 
Baseline adiponectin (ug/ml) 511.82 <0.0001 
Age 2.72 0.10 
Gender 1.85 0.17 
Race 0.04 0.84 
Smoking status 0.61 0.43 
 
Note, Reference groups: Time (baseline); Gender (female); Race (White); Smoking status   
(smokers) 
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Table 5-3 Relationships between changes in BMI and adiponectin: mixed models 
 
 F vaule P value 
Model 1   BMI Δ (kg/m2) 2.50 0.11 
Time  2.49 0.08 
Weight Δ *time 1.31 0.27 
 
Model 2    BMI Δ (kg/m2) 
 
8.67 
 
0.003 
Baseline BMI  (kg/m2) 0.14 0.70 
Baseline adiponectin (ug/ml)   512.63 <0.0001 
Time 0.00 0.96 
Age 2.92 0.09 
Gender 2.95 0.08 
      Race 0.01 0.90 
 
Model 3    BMI Δ (kg/m2) 
 
8.58 
 
0.004 
Baselin BMI (kg/m2) 0.22 0.64 
Baseline adiponectin (ug/ml)   509.14 <0.0001 
Time 0.01 0.94 
Age 2.54 0.11 
Gender 2.83 0.09 
Race 0.03 0.86 
Smoking status 0.72 0.39 
 
      Note, BMI, body mass index 
Reference groups: Time (baseline); Gender (female); Race (White); Smoking status 
(smokers) 
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Table 5-4 Relationships between changes in waist circumference and adiponectin:  
mixed models 
 
 F vaule P value 
Model 1    BMI Δ (kg/m2) 2.50 0.11 
  Time  2.49 0.08 
  Weight Δ *time 1.31 0.27 
 
Model 2    BMI Δ (kg/m2) 
 
8.67 
 
0.003 
Baseline BMI  (kg/m2) 0.14 0.70 
Baseline adiponectin (ug/ml)   512.63 <0.0001 
Time 0.00 0.96 
Age 2.92 0.09 
                  Gender 2.95 0.08 
      Race 0.01 0.90 
 
Model 3    BMI Δ (kg/m2) 
 
8.58 
 
0.004 
Baselin BMI (kg/m2) 0.22 0.64 
Baseline adiponectin (ug/ml)   509.14 <0.0001 
Time 0.01 0.94 
Age 2.54 0.11 
Gender 2.83 0.09 
Race 0.03 0.86 
  Smoking status 0.72 0.39 
 
Note, WC, waist circumference 
Reference groups; Time (baseline); Gender (female); Race (White); Smoking status 
(smokers) 
 
 
 
68 
Table 5-5 Relationships between changes in body fat and adiponectin: mixed models 
 
 F vaule P value 
Model 1   Body fat Δ (%) 3.97 0.04 
     Time  4.59 0.01 
     Body fat*time 2.43 0.09 
 
Model 2   Body fat Δ (%) 
 
9.29 
 
0.002 
 Time 0.09 0.76 
Baseline body fat (%) 0.00 0.96 
Baseline adipnectin (ug/ml) 532.38 <0.0001 
Age 1.97 0.16 
Gender 2.78 0.09 
     Race 0.08 0.78 
 
Model 3   Body fat Δ (%) 
 
9.90 
 
0.002 
Time 0.07 0.79 
Baseline body fat (%) 0.03 0.86 
Baseline adipnectin (ug/ml) 535.68 <0.0001 
Age 1.53 0.21 
Gender 2.35 0.12 
Race 0.11 0.74 
Smoking status 1.41 0.23 
 
Note, Reference groups: Time (baseline); Gender (female); Race (White); Smoking status 
(non smokers) 
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Table 5-6 Relationships between changes in fat free mass and adiponectin: mixed models 
 
 F vaule P value 
Model 1    FFM Δ (kg) 0.06 0.81 
Time  0.17 0.84 
FFM*time 1.34 0.26 
 
Model 2     FFM Δ (kg) 
 
0.09 
 
0.76 
Time 0.00 0.99 
Baseline FFM (kg) 0.00 0.95 
Baseline adiponectin (ug/ml) 485.01 <0.0001 
Age 1.54 0.21 
       Gender 1.02 0.31 
Race 0.21 0.65 
 
Model 3    FFM Δ (kg) 
 
0.05 
 
0.81 
Time 22.21 0.98 
Baseline FFM (kg) 0.01 0.92 
Baseline adiponectin (ug/ml) 480.88 <0.0001 
Age 1.32 0.25 
Gender 1.21 0.27 
Race 0.27 0.60 
Smoking status 0.59 0.44 
 
Note, FFM, fat free mass 
Reference groups: Time (baseline); Gender (female); Race (White); Smoking status (non 
smokers)
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Table 5-7 Relationships between changes in physical measures and adiponectin  over time: estimates from mixed models 
 
Measures Estimate (s.e.) p Estimate (s.e) p 
 
Independent variable: changes in weight over time 
Weight Δ (kg) -0.15 (0.05) 0.002 -0.14 (0.05) 0.003 
Time    0.03 (0.42) 0.93 0.04 (0.42) 0.91 
Baseline weight (kg) -0.002 (0.02) 0.90 -0.005 (0.02) 0.79 
Baseline adiponectin (ug/ml) 0.95 (0.04) <0.0001 0.96 (0.04) <0.0001 
Age -0.06 (0.03) 0.08 -0.05 (0.03) 0.10 
Gender 1.32 (0.99) 0.18 1.35 (0.99) 0.17 
Race 0.11 (0.75) 0.87 0.15 (0.75) 0.84 
Smoking status - - 0.75 (0.96) 0.43 
 
Independent variable: changes in BMI over time  
BMI Δ (kg/m2) -0.39 (0.13) 0.003 -0.39 (0.13) 0.004 
Time    0.02 (0.42) 0.96 0.03 (0.42) 0.94 
Baseline BMI (kg/m2) -0.02(0.06) 0.70 -0.03 (0.06) 0.64 
Baseline adiponectin (ug/ml) 0.95 (0.04) <0.0001 0.96 (0.04) <0.0001 
Age -0.05 (0.03) 0.09 -0.05 (0.03) 0.11 
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Table 5-7 Contd.     
Measures Estimate (s.e.) P Estimate (s.e) P 
Gender 1.52 (0.88) 0.08 1.49 (0.88) 0.09 
Race 0.09(0.76) 0.90 0.81 (0.95) 0.39 
Smoking status - - -1.69 (2.19) 0.43 
 
Independent variable: change in waist circumference over time 
Waist circumference Δ (cm) -0.13 (0.05) 0.006 -0.13 (0.05) 0.006 
Time   6 months     0.07 (0.42) 0.86 0.08 (0.43) 0.85 
\Baseline WC (cm) 0.02 (0.02) 0.39 0.02 (0.03) 0.49 
Baseline adiponectin (ug/ml) 0.95 (0.04) <0.0001 0.95 (0.04) <0.0001 
Age -0.06 (0.03) 0.07 -0.05 (0.03) 0.10 
Gender 0.10 (0.96) 0.30 1.02 (0.96) 0.29 
Race 0.45 (0.74) 0.54 0.47 (0.74) 0.52 
Smoking status - - -0.60 (0.96) 0.53 
 
Independent variable: change in body fat over time 
Body fat Δ (%) -0.21 (0.07) 0.002 -0.21 (0.07) 0.002 
Time   6 months     -0.13 (0.43) 0.76 1.98 (0.35) <0.0001 
Baseline body fat (%) -0.003 (0.06) 0.96 -0.01 (0.06) 0.86 
Baseline adipnectin (ug/ml) 0.95 (0.04) <0.0001 0.96 (0.41) <0.0001 
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Table 5-7 Contd.     
Measures Estimate (s.e.) P Estimate (s.e) P 
Age -0.05 (0.03) 0.16 -0.04 (0.03) 0.21 
Gender 1.70 (1.02) 0.71 1.57 (1.02) 0.12 
Race 0.21 (0.74) 0.78 0.24 (0.74) 0.74 
Smoking status - - 1.11 (0.94) 0.23 
 
Independent variable: change in fat free mass over time 
Fat free mass Δ (kg) -0.01 (0.04) 0.76 -0.009 (0.04) 0.81 
Time    0.002 (0.43) 0.99 0.007 (0.43) 0.98 
Baseline fat free mass (kg) 0.0014 (0.03) 0.95 -0.002 (0.03) 0.92 
Baseline adiponectin (ug/ml) 0.96 (0.04) <0.0001 0.96 (0.04) <0.0001 
Age 0.10 (0.07) 0.14 -0.04 (0.03) 0.25 
Gender 1.56 (1.54) 0.52 1.72 (1.56) 0.27 
Race -0.04 (0.03) 0.21 0.40 (0.78) 0.60 
Smoking status - - -0.77 (1.00) 0.44 
 
Note, BMI, body mass index; WC, waist circumference 
Reference groups used: Time (baseline); Gender (female); Race (White); Smoking status (smokers) 
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6.0    GENERAL DISCUSSION 
6.1    OVERALL SUMMARY 
 
This dissertation, designed as three research papers, aimed to examine relationships between 
diet, weight loss, insulin resistance and adiponectin levels among overweight/obese adults who 
were participating in a behavioral intervention for weight loss. Based on the available literature 
suggesting a protective effect of adiponectin on the development of diabetes and CVD, the 
premise for the three studies was that a lifestyle intervention may increase adiponectin, which in 
turn may decrease insulin resistance, and that weight loss during a behavioral intervention may 
increase adiponectin levels.  
 The first study compared the effect of a STD-D and a LOV-D on changes in adiponectin 
levels at six months. This was an ancillary study to the PREFER trial, an 18-month clinical trial 
of a behavioral weight loss intervention. The same behavioral intervention was delivered to both 
dietary groups; the only difference was that the LOV-D participants were instructed to eliminate 
meat, poultry, and fish from their diet. Eligible participants included 143 overweight/obese 
adults (STD-D = 79; LOV-D = 64) with a mean BMI of 33.7 kg/m2. The sample was 88% 
female, 67% White, and 44.2 ± 8.5 years old. Results of this analysis revealed that the 
adiponectin levels increased significantly in response to both STD-D and LOV-D with no 
significant differences in the changes of adiponectin levels between the two groups.  
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 One could argue that the null findings might be due to the LOV-D diet group not strictly 
adhering to the prescribed diet during the study period. However, a comparison of changes in 
adiponectin levels between the STD-D and the 100% adherent LOV-D groups also showed no 
statistically significant differences in the changes of total and HMW adiponectin levels between 
100% adherent LOV-D and the STD-D groups.  Furthermore, we found significant associations 
between changes in adiponectin levels and weight loss independent of diet types such that the 
greater the weight loss, the larger was the increase in adiponectin levels.  These findings suggest 
that more than one type of diet can be followed to increase adiponectin levels as long as weight 
loss is achieved and maintained. Since weight loss at the higher quartile was associated with 
greater increases in adiponectin levels, a weight loss close to 10% might be necessary for a 
significant increase in adiponectin levels.   
 The second study determined whether baseline levels or intervention-associated changes 
in total and high molecular weight adiponectin levels were associated with insulin resistance at 
six months. The study design and sample study were the same as in the first study. Analysis of 
this study revealed that the increase in total adiponectin was inversely associated with the 
decrease in HOMA independent of baseline weight and weight change suggesting that total 
adiponectin contributed to improved insulin sensitivity independent of baseline weight and 
weight loss. However, the significant association between changes in HMW adiponectin level 
and HOMA score was no longer present after adjustment for weight change.  
 These findings suggest that a measurement of only total adiponectin might be adequate to 
examine these relationships and the role of HMW adiponectin level is no more important or at 
least similar to that of total adiponectin in relation to weight loss and insulin sensitivity. 
Association of six-month changes in adiponectin and the HOMA score was modest compared to 
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baseline measures, suggesting that the cross-sectional measure of total adiponectin might be a 
comparable indicator in relation to measuring insulin sensitivity among overweight or obese 
adults. Since total adiponectin contributed to better insulin sensitivity, the study highlights the 
importance of adiponectin in the development of IR and subsequent development of type 2 
diabetes. 
The third study assessed the longitudinal relationships of weight, waist circumference and 
body composition with adiponectin level after six and 12 months of participation in a behavioral 
intervention for weight loss.  This was a secondary data analysis of the SMART trial, a 24 month 
clinical trial of behavioral weight loss intervention. All participants received standard behavioral 
treatment for weight loss that included calorie, fat and physical activity goals and group 
intervention sessions that provided strategies and guidance to help achieve a healthful lifestyle. 
The sample included 133 overweight/obese adults with a mean BMI of 33.4 ± 4.7 kg/m2 and was 
86% female, 81% White, and 45.3 ± 8.8 years old. We measured circulating adiponectin level, 
weight, waist circumference and body composition at baseline, six and 12 months. Retention at 
six months was 91% and 85% at 12 months. A longitudinal analysis with adiponectin levels as 
the dependent variable showed significant increase in adiponectin with weight reduction, waist 
circumference and percent body fat; while no such association was found with changes in fat free 
mass and adiponectin levels over time. These findings suggest a negative feedback of obesity on 
adiponectin and further provide evidence that the production and secretion of adiponectin is 
modified by the adipose tissue. 
Taken together, the findings from these three studies suggest the beneficial effects of the 
intervention on changes in adiponectin levels, insulin resistance, weight, percent body fat and 
waist circumference. Overall our results suggest that weight loss is more important than the type 
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of diet followed in increasing adiponectin levels. Increased adiponectin levels contribute to 
lowering HOMA scores and the role of HMW adiponectin levels in relation to weight loss and 
insulin sensitivity is similar to that of total adiponectin. Furthermore, interventions that target 
long-term weight loss accompanied by reduction in waist circumference, percent body fat 
enhance adiponectin levels thereby reducing the risk of developing several chronic diseases, such 
as diabetes and CVD.   
 
6.2    LIMITATIONS 
 
The PREFER and SMART trials provided a unique opportunity to investigate the 
relationships between diet, weight loss, insulin resistance and adiponectin levels among 
overweight/obese adults. However, there were some limitations applicable to all three studies 
that should be considered when interpreting the findings from this dissertation. The dietary 
measures were assessed with self-reported dietary intake. Additionally, dietary data collected 
with the 3-day Food Records may not represent dietary intake over six months. The accepted 
biomarkers for dietary intake are not easily available; therefore, we must rely on self-reported 
dietary instruments and use what is considered the best approach. The measures of IR included a 
surrogate marker, HOMA; however, HOMA was derived from the mathematical model and has 
been shown to be an adequate indicator of IR and has been used in many epidemiological and 
clinical studies 70, 77. Body composition was evaluated with BIA, which is not considered the 
gold standard. However, the measurement of body composition with BIA has been shown to 
have good accuracy and reliability and has been suggested as a screening tool in clinical practice 
and in population based research 132. Another limitation included a small representation of males 
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as has been observed in other weight-loss trials, which may be due to a lower percentage of men 
than women trying to lose weight 136. Most individuals were female, White, and employed full 
time limiting the generalizability of these findings to populations with these characteristics. 
6.3    PUBLIC HEALTH SIGNIFICANCE 
Obesity is a chronic disorder that is associated with increased risk for several chronic diseases 
including diabetes, hypertension, cardiovascular disease and some cancers89-91, 137, 138. Although 
our understanding of CVD and obesity has improved substantially in recent years, CVD still 
remains the major cause of morbidity and mortality among Americans. A recent National Health 
Interview Survey showed that the prevalence of overweight/obesity has plateaued; however, it is 
still at the level of an epidemic and remains a major and significant public health concern139.  A 
higher level of adiponectin secreted by adipose tissue itself is suggested to protect against 
developing diabetes and CVD.  Thus, interventions that enhance adiponectin secretion or action 
may have potential for CVD and diabetes risk reduction 
Given the negative associations between elevated adiponectin levels and the multiple 
indices of obesity, the findings of the three studies emphasize the importance of weight loss as a 
significant public health preventive measure to enhance adiponectin levels among the studied 
population. Prevention of disease, death and disabilities related to CVD requires sustained health 
behavior or lifestyle changes. Even modest sustained health behavior or lifestyle changes can 
reduce CVD morbidity and mortality substantially. Thus, interventions that target long-term 
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weight loss that results in reduced waist circumference and percent body fat help enhance 
adiponectin levels, thereby reducing the risk for the development of diabetes and CVD.  
 
6.4    FUTURE RESEARCH 
 
As obesity, diabetes and CVD are the result of several factors including genetic, environmental 
and behavioral, a better understanding of adiponectin physiology in relation to obesity, diabetes 
and CVD could be of value in identifying means to increase adiponectin levels.   It is also 
important to keep in mind that weight and dietary intake had changed simultaneously once the 
intervention started in both PREFER and SMART trials. Thus, it is difficult to distinguish if 
observed increased adiponectin levels was due to changes in dietary intake or from the weight 
loss per se. Future studies examining the effects of dietary composition in weight-stable 
population are needed to elucidate the role of weight in the relation between the two.   
Although we did not observe differences in adiponectin changes in response to both 
STD-D and LOV-D in the study, we cannot rule out the possibility of specific food groups 
having positive effects on adiponectin levels. In particular, cross-sectional studies have 
suggested that increased adiponectin levels are observed with consumption of a high intake of 
dietary fiber33, 34, 99, 140, deep yellow and green vegetables32 and moderate alcohol intake34. 
Longitudinal studies are required to determine further relationships between the food groups and 
adiponectin levels.  
It has been well established that obesity is a major risk factor for the development of 
diabetes and CVD, however, the mechanism by which adipose tissue contributes to progression 
of  diabetes and CVD is not well understood. Adipose tissue is now recognized as an active 
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endocrine organ secreting several hormones and a diverse range of other protein factors in recent 
years16. This dissertation was limited to the measurement of only adiponectin levels. It is 
imperative to further explore the associations of adiponectin with other markers to better 
understand their contribution to the development of diabetes and CVD.  
Prior studies have reported that a higher fat accrual in the abdominal area may have more 
detrimental effects on diabetes and CVD risk than fat accrued in the lower extremities. Our 
measure of body composition with BIA did not differentiate between visceral and subcutaneous 
adipocytes.  Therefore, it is important to carry out future studies investigating the changes in 
regional fat that might help understand how changes in different regional adipose tissue 
influence changes in adiponectin levels. These studies need to be carried out in populations with 
diverse ethnic background and wide age range, incorporating both genders allowing the findings 
to be applicable to a general population. 
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APPENDIX A 
FLOW CHART: PREFER TRIAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screened for eligibility by phone (n=932) 
 
Sent screening packets (n=425) 
 
Invited to Information Session (n=298) 
 
Returned 5-Day Food Diary (n=218) 
 
Attended Baseline Assessment (n=204) 
 
Randomized (n=200) 
 
Ineligible (n=9) 
 
PREFER - YES 
 
PREFER - YES 
 
STD-D (N=48) 
 
LOV-D (N=35) STD-D (N=48) 
 
LOV-D (N=45) 
Completed 6-month 
assessment 
(n=42, 87.5%) 
 
Completed 6-month 
assessment 
     (n=29, 82.9%) 
 
Completed 6-month 
assessment 
        (n=41, 85.4%) 
 
Completed 6-month 
assessment 
           (n=39, 86.7%) 
 
STD-D = Standard Diet; LOV-D =  Lacto-Ovo-Vegetarian Diet 
 
Discarded (n=15) 
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APPENDIX B 
FLOW CHART: SMART TRIAL 
 
 
 
Screened for eligibility by phone (n=452) 
 
Sent screening packets (n=307) 
 
Invited to Information Session (n=189) 
 
Returned 5-Day Food Diary (n=140) 
 
Attended Baseline Assessment (n=138) 
 
Randomized (n=136) 
 
PR (N=46)     PDA (N=44) PDA+FB (N=46) 
Completed 6-month 
assessment 
(n=39, 85%) 
 
Completed 6-month 
assessment 
(n=41, 93%) 
Completed 6-month 
assessment 
(n=43, 93%) 
 
Completed 12-month 
assessment 
(n=36, 78%) 
 
 
Completed 12-month 
assessment 
(n=39,89%) 
 
Completed 12-month 
assessment 
(n=40, 87%) 
 
PR = paper record; PDA = personal digital assistant; PDA+FB = PDA and feedback  
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